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Thirty-one years after the discovery and isolation of the human immunodeficiency 
virus (HIV) by French and American scientists, much progress has been made in 
basic research, clinical treatment, and public heath prevention.  Although, much 
evidence of mother-to-child-transmission (MTCT) of HIV has been amassed 
since then, not much of it describes the effects of HIV on the nutrient composition 
of breast milk. 
 
The aim of this study was to determine the effects of HIV on the nutrient 
composition of breast milk, by studying two groups of adult lactating respondents 
from the same socio-economic background, who were chosen randomly and 
participated voluntarily.  The study population consisted of 60 breastfeeding 
mothers, divided into two groups of 30 mothers each.  Group one represented 
the control group of HIV non-infected mothers whereas group two consisted of 
HIV-infected mothers who did not receive any treatment. 
 
After a registered medical nurse took blood and breast milk samples, analysis 
was done on ethylenediamine tetra-acetic acid (EDTA) whole blood to determine 
the haematological and immunological parameters and breast milk was analyzed 
for nutrient composition.  Standard laboratory operating procedures (SOP) were 
followed, throughout, to determine the parameters of the blood and breast milk 
samples. 
 
Results showed that associations between the socio-economic statuses (SES) of 
the two respondent groups could be established.  Albeit differences were not 
significant, some were, however, detected in the number of people contributing to 
the household income of the respondents (p = 0.0051), their employment status 
(p < 0.0001) and the availability of water sources (p = 0.1124).  It is believed that 
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factors, such as the prevalence of HIV, if related to the different levels of SES 
may play an important role in the outcome of the health statuses of individuals at 
different levels of society.  By implication, it is not the different levels of SES, but 
rather factors related to the different levels of SES that have an impact.  
 
Significant differences could be seen in the haematological variables between 
the two respondent groups: Red blood cell count (RBC) (p < 0.0001), hemoglobin 
(Hb) levels (p = 0.0119), hematocrit (Hct) (p = 0.0031), mean corpuscular volume 
(MCV) (p = 0.0005), mean corpuscular hemoglobin (MCH) (p = 0.0043) and 
monocyte count (p = 0.0275).  These differences, however, were not significant 
to this study.  
 
Other differences that were significant were immunological parameters between 
the two respondent groups: CD4 cell count (p < 0.0001) and viral load, done only 
on the blood of the HIV-infected respondent group.  The CD4 cell count is used 
as a guideline for the initiation of treatment for HIV-infected persons and is 
required to accurately assess the immune status of any patient at any given time.  
The viral load has long been established as a strong predictor of the rate of 
disease progression.  
 
The only significant difference in the breast milk composition was reflected in the 
following variables between the two groups: percentage (%) proteins (p < 0.0001) 
and calcium levels (p = 0.0081).  The median and mean values of the percentage 
proteins were elevated in the subject group of mothers living with HIV, while 
calcium levels in the same group showed a decrease in both median and mean 
values. 
 
The lack of significant differences between the groups might be due to the small 
study population.  If nothing else, this study highlights the need for further trials to 
evaluate the true effects of HIV on the nutrient composition of breast milk. 
Key word: HIV, pregnant woman, breastfeeding 
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1.1 BACKGROUND 
 
The first case of human immunodeficiency virus (HIV) was reported in South 
Africa in 1982.  Since then the epidemic has spread at an alarming rate.  South 
Africa is one of the countries with the highest HIV prevalence rate in the world.  
This is why HIV and AIDS (acquired immune deficiency syndrome) are rated 
amongst the most important factors that have been impacting social integration in 
general and family life as a whole.  Regardless of race, class, gender and age 
the HIV epidemic has spread rapidly among black heterosexuals of both 
genders, and as such, is affecting this ethnic group’s lives extensively (Smit, 
2007; Crothers, 2001). 
 
In sub-Saharan Africa, women are more likely to become HIV-infected than men.  
The most recent prevalence data shows that 13 women become HIV infected for 
every 10 men infected with HIV (UNAIDS, 2010).  The most alarming factor in 
South Africa is the increase in child mortality that increased from 56.3 per 1 000 
in 1990 to 65.5 per 1 000 in 2005 (Smit, 2007; UNAIDS, 2005), and it is further 
estimated that 50% of HIV-infected infants will die before the age of two.   
According to Gribble, McGrath, MacLaine & Lhotska (2011), guided decisions 
related to child nutrition and the improvement of quality of life are necessary to 
reduce morbidity and mortality among HIV-infected children.  
 
Statistics South Africa (StatsSA) estimated South Africa's population at 50.59 
million in 2011 with an overall HIV prevalence rate of approximately 10.6%, and 
people living with HIV at approximately 5.38 million.  According to StatsSA, in 
2011 approximately 16.6% adults between 15-49 years of age were infected with 
HIV and roughly 63 600 new HIV infections were among children aged 0 – 14 
years (StatsSA, 2011). 
CHAPTER 1 
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HIV transmission from mother to child can happen during pregnancy, delivery or 
postnatal through breastfeeding.  The latter type of transmission has emerged as 
an important mode of pediatric acquisition in the African breastfeeding population 
which is a major cause of child mortality in sub-Saharan Africa (Becquet, Bland, 
Leroy, Rollins, Ekouevi, Coutsoudis, Dabis, Coovadia, Salamon & Newell, 2009; 
Coovadia & Bland, 2007).   
 
Since the 1980s breastfeeding has been well documented as a vehicle for HIV 
transmission.  This poses a serious concern for the 15.7 million HIV-infected 
women of reproductive age (15-49) across the globe (Clasen, 2011), but more so 
in sub-Saharan Africa where MTCT of HIV is of particular concern.  It is in this 
region that eight out of every ten women infected with HIV live and where 53% of 
infants under the age of four months are exclusively being breast fed (Clasen, 
2011).  Of the more than ten million children who die each year in the developing 
world, about 60% of these deaths are preventable.  Labbok, Clark & Goldman 
(2004), posit that breastfeeding is the most effective means of reducing the death 
rate of children younger than five years.   
 
The avoidance of breastfeeding in resource-limited countries puts infants at a 
much higher risk of infection and death.  Thus to strike a balance between 
preventing HIV transmission and protecting infants from malnutrition and disease 
becomes difficult (Clasen, 2011).  In South Africa limited research is available on 
the nutrient composition of HIV-infected mothers’ breast milk.  
 
1.2 AIM     
 
The main aim of this study was to investigate the effect of HIV on the nutrient 
composition of breast milk. 
 
 
 
 3 
1.3 STRUCTURE OF THIS DISSERTATION 
 
     The structure of this thesis is as follows: 
 Chapter I is an introductory chapter that gives the background of the study. 
 Chapter 2 is an extensive literature survey of the most critical information 
needed to understand and interpret the aim and results of this study.  
 Chapter 3 provides detailed information about specimen preparation and all 
methological procedures used in this study. 
 Chapter 4 provides the results of the study. 
 Chapter 5 provides the discussion of this study. 
 Chapter 6 summarizes the study by presenting a discussion and conclusion, 
with recommendations. 
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2.1 HISTORICAL BACKGROUND 
 
The disease caused by HIV was first identified in 1981 among two groups - one 
in San Francisco and the other in New York, when young homosexual men 
presented with opportunistic infections associated with severe immune deficiency 
like Pneumocystis pneumonia (PCP) or aggressive Kaposi sarcoma.  According 
to Bennett, it was only two years later that the human immunodeficiency (HI) 
virus itself was identified and various other causes including lifestyle factors, 
chronic drug abuse, and other infectious agents came to be associated with HIV 
Infection. 
 
At that stage, HIV testing was not yet available and the HIV epidemic spread 
rapidly.  Although society was unaware of the disease, clear clinical implications 
had arisen.  Prior to the recognition of HIV, only one case of Pneumocystis 
pneumonia, not clearly associated with immune suppression, had been 
diagnosed in the United States between January 1976 and June 1980 (Bennett, 
2011).  A study that was published in December 1980 reported the isolation and 
characterization of the first human retrovirus, the human T cell leukemia virus 
(HTLV) (Blattner, 1991; Poiesz, Ruscetti, Gazdar, Bunn, Minna & Gallo, 1980).  
French scientists were the first people to isolate the virus in 1983 (Blattner, 1991; 
Barre-Sinoussi, Chermann, Rey, Nugeyre, Chamaret, Gruest, Dauget, Axler-Blin, 
Vézinet-Brun, Rouzioux, Rozenbaum & Montagnier, 1983).  Owing to this 
breakthrough, a British seaman, who died of progressive immunodeficiency in 
1959, has become the first person documented with HIV infection (Blattner, 
1991; Crobitt, Bailey & William, 1990).  
CHAPTER 2 
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The HI virus is blood-borne and sexually transmissible. This virus is typically 
transmitted via sexual intercourse, shared intravenous drug paraphernalia, and 
through MTCT, which can occur during the birth process or during breastfeeding.  
What is also common is co-infection with other viruses that share similar routes 
of transmission such as hepatitis B, hepatitis C, and human herpes virus 8 
(Bennett, 2011).   
 
The incubation period of HIV from exposure to disease ranges from eight to ten 
years.  That is characterized, according to Klatt (2011) and Blattner (1991), by a 
progressive depletion of CD4-positive T lymphocytes, as well as effects on other 
immune and central nervous system cell populations.  Currently, two strains of 
the virus have been identified.  HIV-1 originated from one or more cross-species 
transfers from chimpanzees in Central Africa, whereas HIV-2 is related to viruses 
that infect sooty mangabeys in Western Africa.  Although HIV-1 and HIV-2 strains 
are superficially similar, each contains unique genes and has its own replication 
process (Bennett, 2011; Klatt, 2011). 
 
Because of the sexual transmissibility of HIV-infection, the virus has been 
stigmatized and linked to sexual promiscuity.  Stigmatization has led to 
discrimination against those infected, which in turn has resulted in a reluctance to 
be tested for the virus.  However, since HIV causes relentless immune decline, 
eventual premature death in the vast majority of infected people and the fact that 
it is incurable has made testing crucial (Bennett, 2011; Skinner & Mfecane, 
2004).   
 
Despite many advantages being made globally in fighting the HIV epidemic, too 
many people are still getting sick and too many people are dying.  The past 
decade has seen a historically unprecedented global response to the unique 
threat the HIV epidemic poses to human development (WHO, UNAIDS & 
UNICEF, 2011; Blattner, 1991). WHO (World Health Organization), UNAIDS 
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(Joint United Programme on HIV and AIDS) and UNICEF (United Nations 
Children’s Fund) (2011) state that at the beginning of the 21st century, the 
international community faced formidable health and development challenges, 
none more so than countries in the poorest region of the world: sub-Saharan 
Africa.  In this region, the rapidly expanding HIV epidemic dramatically reversed 
the decades of progress on the key developmental indicators, such as infant 
mortality and life expectancy (WHO, UNAIDS & UNICEF, 2011). 
 
2.1.1 What is HIV? 
 
HIV is a virus that infects cells of the human immune system and destroys or 
impairs their function (UNAIDS, 2008).  It affects mostly the CD4 positive T cells 
and macrophages – a key component of the cellular immune system.  Infection 
results in the progressive deterioration of the immune system, leading to immune 
deficiency.  When the immune system can no longer fulfill its role of fighting off 
infections and diseases it is considered deficient.  Once people are 
immunodeficient, they become susceptible to a wide range of infections known 
as opportunistic infections. They are thus called because they take advantage of 
a weakened immune response (UNAIDS, 2008).  
 
2.1.2 What is AIDS? 
 
AIDS is an acronym for Acquired Immune Deficiency Syndrome, and is the result 
of HIV infection (UNAIDS, 2008). 
Acquired means to get: the virus infects people, leading to the associated 
symptoms. 
Immune means protected: it refers to the body’s ability to fight off infections. 
Deficiency means lack of: an HIV-infected person lacks protection and therefore 
cannot fight off common diseases. 
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Syndrome means a collection of signs and symptoms. 
 
2.2 EPIDEMIOLOGY 
 
Miller-Keane (2013) states that epidemiology is the science concerned with the 
study of the factors determining and influencing the frequency and distribution of 
disease, injury, and other health-related events and their causes in a defined 
human population for the purpose of establishing programs to prevent and 
control their development and spread. 
 
2.2.1 Global 
 
The global incidence of HIV infection peaked in the mid-1990s when more than 
three million people were being newly infected every year.  AIDS then became 
one of the leading causes of adults dying in sub-Saharan Africa.  Since 2006, 
more than 2.2 million people have died each year from AIDS-related causes 
(WHO, UNAIDS & UNICEF, 2011; UNAIDS 2009; WHO, 2004).  According to the 
WHO and UNAIDS, an estimated 2.7 million people became newly infected with 
HIV in 2010.  In Sub-Saharan Africa, where the majority of new HIV infections 
continue to occur, an estimated 1.8 million people became infected in 2009 
(UNAIDS, Global Report, 2010).  An estimated 34 million people have been living 
with HIV as from 2010, 16.8 million being women and 3.4 million children under 
the age of 15 (see Table 2.1 UNICEF, 2012). 
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TABLE 2.1: Global summary of the AIDS pandemic, 2011 
Number of people living with HIV in 2011 
Total 34,2 million                          [31,8 – 35,9] 
Adults 30,7 million                          [28,6 – 32,2] 
Women 16,7 million                           [15.7 – 17.8] 
Children under 15 years 3.4 million                                [3.1 – 3.9] 
People newly infected with HIV in 2011 
Total 2.5 million                               [2.2 – 2.8] 
Adults 2.2 million                               [2.0 – 2.4] 
Children under 15 years 330,0000                  [280,000 – 380,000] 
AIDS deaths in 2011 
Total 1.7 million                                [1.6 – 1.9] 
Adults 1.5 million                             [1.3 – 1.7] 
Children under 15 years 230,000                    [200,000 – 270,000] 
 
 
 
2.2.2 Sub-Saharan Africa 
 
Approximately 33.4 million people worldwide - one % (percent) of the global adult 
population aged 15-49 years - are currently infected with HIV.  The vast majority 
of infections remain in sub-Saharan Africa, where 5.2% of the population is 
thought to be infected (UNICEF, 2012; Bennet, 2011; Klatt, 2011).  WHO and 
UNAIDS estimated in 2007 that 15.4 million (13.9-16.6 million), almost half the 
Note: The numbers in brackets are ranges around the estimates that define the boundaries within 
which the actual numbers lie based on the best available information. 
Source: UNAIDS, 2012. 
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population of people living with HIV and AIDS, were women.  In sub-Saharan 
Africa this number accounted for 68% of the world’s disease burden 
(Sahasrabuddhe & Vermund 2009; McGowan, 2009). 
 
Sub-Saharan Africa continues to bear an inordinate share of the global HIV 
burden.  Though the number of new infections on the continent seems to have 
peaked in the mid-1990s, the epidemic continues to be a major challenge to the 
health and development of many African nations.  The epidemic varies from 
country to country across the continent, with prevalence estimates ranging from 
0.1 % in Madagascar to more than 15% in some of the countries in the southern 
cone.  The epidemics in sub-Saharan Africa vary considerably, with South Africa 
still the most severely affected (USAID, 2011). 
 
Sub-Saharan Africa is the region with the highest prevalence of HIV infection 
among women of reproductive age (WHO, UNAIDS & UNICEF, 2011).  This 
region also accounted for 67 % of the world’s AIDS-related deaths in 2010 
(UNICEF, 2012). Table 2.2 summarizes the statistics of the AIDS pandemic for 
sub-Saharan Africa for the year 2009. 
 
Table 2.2: AIDS statistics for sub-Saharan Africa, 2009 (UNAIDS) 
 People living 
with HIV 
People newly 
infected with 
HIV 
Children living 
with HIV 
AIDS-related 
deaths 
SUB-
SAHARAN 
AFRICA 
22.5 million 
[20.9-24.2 million] 
1.8 million 
[1.6-2.0 million] 
2.3 million 
[1.4-3.1 million] 
1.3 million 
[1.1-1.5 million] 
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2.2.3 South Africa 
 
South Africa has a population of approximately 50.6 million people, accounting 
for 7% of the world’s population (StatsSA, July 2011).  Of these 50.6 million 
people, Statistics South Africa (StatsSA) estimated that 5.38 million people (17% 
of the global burden) were living with HIV in 2011.  HIV prevalence for the adult 
population (15-29 years) has been estimated at 16.6%, and the overall 
population prevalence rate at 10.6%. This could be due to the South African 
Government’s slowness in admitting to having an HIV epidemic and that AIDS 
was even a problem.  Changes are now occurring, albeit slowly and at an 
unknown cost (Bennett, 2011). 
 
In South Africa, both immediate and underlying factors are contributing to the 
transmission of HIV.  Immediate factors of the HIV and AIDS epidemic include 
behavioral factors such as frequently unprotected sex, multiple sexual partners, 
and the high prevalence of sexually transmitted diseases (STDs).  Underlying 
factors include poverty, the migrant labour system, commercial sex, illiteracy, 
stigmatization, discrimination, the low status of women and the lack of formal 
education.  With more than five million people living with HIV and AIDS, South 
Africa still has the greatest disease burden of any single country in the world 
(Sahasrabuddhe & Vermund 2009) and remains the area most heavily affected 
by the HIV epidemic (UNICEF, 2012). 
 
Data from an antenatal survey suggests that HIV prevalence had plateaued, 
although at a high level of nearly 30%.  This national figure masks provincial and 
district level differences with some districts in KwaZulu-Natal being above 40% to 
several districts in the Northern Cape and Western Cape below 10%.  StatsSA 
(2011) identifies that high prevalence in access to ARVs represents longer life 
expectancy and not increased incidence of infection.  StatsSA (2011) attributes 
this increase in life expectancy to the impact of antiretroviral (ARV) therapy.  
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However, StatsSA (2011) estimates that the disease still has a dramatic impact 
on life expectancy, which is currently 54.9 years for men and 59.1 years for 
women.  Figures 2.1 and 2.2 show the HIV antenatal seroprevalence rates from 
1990 to 2009 in South Africa as well as the districts in South Africa which have 
been influenced the most. 
 
Figure 2.1: HIV Antenatal seroprevalence rates, 1990-2009 
Source:  Source: South African Department of Health (b), 2011) 
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Figure 2.2: HIV Antenatal Seroprevalence Rates in 15 Districts with the 
Highest Rates in South Africa (Source: South African Department of 
Health (b), 2011) 
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2.2.3.1 Trends of HIV Transmission in South Africa 
HIV infection is much higher in the South African black population than any other 
race groups.  Adult women aged 15 years and above are more likely to be HIV 
positive than men of the same age and young women between 20 and 24 years 
are four times more likely than males of the same age to have the HI virus (South 
African Department of Health (a), 2011).  The difference is even higher in 
teenage girls.  It has been estimated that people living with HIV show 
considerable clustering in the eastern parts of the country, with the majority of 
adult people living with HIV (54%) located in Gauteng and KwaZulu-Natal (South 
African Department of Health (a), 2011).  The levels of HIV in the informal 
settlements in urban areas are also high.  Furthermore, a low SES is associated 
with HIV infection, since those who work in the informal sector have the overall 
highest HIV prevalence with almost a third of the African informal workers being 
HIV positive.  Among women, those with less disposable income have a higher 
risk of being HIV positive (South Africa: Department of Health (a), 2011). 
 
2.2.4 Children 
 
More than 90% of children living with HIV and AIDS come from sub-Saharan 
Africa (Sahasrabuddhe & Vermund 2009).  Diarrhea and pneumonia respectively 
are the third and fourth biggest causes of HIV-infected child-deaths under the 
age of five in South Africa (Doherty, Sanders, Goga & Jackson, 2010).  De Cock 
and co-workers (2000) maintain that the global epidemiology of pediatric HIV 
infections reflect that of HIV infections in women.  These estimates are 
equivalent to approximately one child being infected every second day in the 
United State, one every day in Europe, two a week in Asia, and over 1000 a day 
in Africa (McIntyre & Lallement, 2008).   
 
The HIV pandemic has had a dramatic impact on child mortality, with 380 000 
children having died of AIDS-related diseases.  In 2006 an estimated 2.3 million 
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children under 15 years were living with the virus, mainly as a result of MTCT.  
Estimates, according to UNAIDS (2007), showed that around 420 000 children 
(350 000-540 000) were newly infected with HIV in 2007, again mainly through 
MTCT.  More than 90% of these children are living in sub-Saharan Africa.  The 
provision of a combination of antiretroviral treatment (ART) during pregnancy, 
ongoing for those with higher CD4 cell counts, together with the use of 
replacement feeding has become the standard for caring for HIV-infected 
pregnant women in well-resourced settings.  As a result, there has been a drop in 
MTCT rates to below two percent (McIntyre & Gray, 2009; Fowler et al., 2007; 
Newell & Thorne, 2004). 
Around 390 000 children were infected with HIV in 2010, bringing the total 
number of children infected with HIV to 3.4 million.  All these children were under 
15 years of age and more than 90% of them were living in sub-Saharan Africa 
(UNICEF, 2012). 
 
2.3 HIV TRANSMISSION PHYSIOLOGY 
 
HIV transmission primarily occurs through sexual contact.  The virus breaches 
the epithelial barrier at sites of inflammation or micro-abrasions and via contact 
with Langerhans and dendritic cells.  During this process HIV is transferred from 
the mucosal surface to the underlying target cells.  The cells infected at the 
mucosal surface then present the HI virus to the CD4-positive lymphocytes and 
the virus is transported to deeper tissue (Figure 2.3).  The HI virus can be 
detected in regional lymph nodes as early as two days after infection and then in 
the blood within 7 days.  Following that, Viremia which has a dramatic impact on 
the immune system and leads to the destruction of CD4 memory T cells, occurs.  
This process mainly manifests in the gut-associated lymphoid tissue, where a 
large amount of these cells are located.  It results in a crippling effect on the 
prime defenses against infection (Kuhn et al., 2007; Iliff et al., 2005; Brenchley et 
al., 2004; Coutsoudis, Pillay, Kuhn, Spooner, Tsia & Coovadia, 2001). 
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2.4 IMMUNOLOGY AND HOST DEFENSES 
 
The adaptive immune response consists of two branches. The first branch, the 
humoral branch, controls infections through antibodies.  Antibodies are proteins 
which are able to attach to antigens (such as a virus) because of the former’s 
structures.  When an antibody has bound to an antigen through a “lock and key” 
interaction, the invading pathogen can be destroyed through a number of 
intracellular and extracellular mechanisms (Klatt, 2011; Geise & Duerr, 2009; 
Goepfert, 2003).  If the antibodies bind to the pathogen before they infect their 
target cells, the antibodies can provide a “sterilizing immunity”- that is, the 
immune response can prevent the establishment of any detectable infection.  
The cellular immune system is the second branch of the immune response and is 
much more complex (Klatt, 2011; Geise & Duerr, 2009; Goepfert, 2003).        
This system works best in clearing established infections such as when antigen-
Figure 2.3: Mucosal transmission of HIV-1 probably occurs through multiple pathways. 
Target cells in the subepithelial area include CD4+ lymphocytes, macrophages and 
dendritic cells. Mucosal inflammation and epithelial disruption secondary to sexually 
transmitted infections (STIs) increase the risk of HIV-1 transmission trough recruitment of 
additional target cells. Adapted from: MgGowan, 2006 
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presenting cells respond to selected pathogen peptides.  When the antigen-
presenting cells are detected by cytotoxic T cells, the pathogen peptides 
containing nine to 15 amino acids (epitopes) are displayed on the surface of the 
infected cells in conjunction with a “self” antigen (HLA).  These infected cells can 
be destroyed either by phagocytosis, cytokine release or cell lysis (Klatt, 2011; 
Geise & Duerr, 2009; Goepfert, 2003).  
 
The humoral branch of the immune system develops antibodies to the various 
protein constituents of HIV.  Seeing that the structure of HIV is very complex and 
the HIV envelope protein limits antibody access to these surface proteins, those 
parts of the HIV envelope involved in T-cell binding are shielded by glycosolation 
and conformational masking, which shields the HIV from interaction with 
antibodies.  Escaped isolates are easily developed and limit the antibody effects 
in neutralizing the circulating virus (Kwong et al., 1998).  The proteins on the HIV 
envelope change due to rapid viral evolution, which makes it difficult for existing 
antibodies to recognize these new isolates.  The CD8-positive lymphocytes 
dominate the cellular arm of the immune system and can control the infection 
temporarily through the recognition of infected cells, apoptosis, and cytokine 
secretion (Klatt, 2011; Geise & Duerr, 2009; Goepfert, 2003). 
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2.5 HIV LIFE CYCLE 
 
The life cycle of HIV can be described in six steps (see Figure 2.4): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.  Binding and Fusion: HIV begins its life cycle when it binds to a CD4 receptor 
and one of two co-receptors on the surface of a CD4+ T-lymphocyte.  The virus 
then fuses with the host cell.  After fusion, the virus releases ribonucleic acid 
(RNA) into the host cell. 
2. Reverse Transcription: An HIV enzyme, called reverse transcriptase, 
converts the single-stranded HIV RNA to double-stranded HIV deoxyribonucleic 
acid (DNA). 
Figure 2.4: The aspects of the HIV life cycle (Adapted from: http://aidsinfo.nih.gov) 
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3.  Integration: The newly formed HIV DNA enters the host cell nucleus, where 
an HIV enzyme called integrase “hides” the HIV DNA within the host cell’s own 
DNA.  The integrated HIV DNA, called provirus, may remain inactive for several 
years, producing new copies of HIV or none. 
4. Transcription: When the host cell receives a signal to become active, the 
provirus uses a host enzyme called RNA polymerase to create copies of the HIV 
genomic material, as well as shorter strands of RNA called messenger RNA.  
These are used as a blueprint to make long chains of HIV proteins. 
5. Assembly: An HIV enzyme called protease cuts the long chains of HIV 
proteins into smaller individual proteins.  As the smaller HIV proteins come 
together with copies of HIV’s RNA genetic material, a new virus is assembled. 
6. Budding: The newly assembled virus pushes out (“buds”) from the host cell.  
During budding, the new virus steals part of the original cell’s outer envelope. 
This envelope, which acts as a covering, is studded with protein/sugar 
combinations called HIV glycoproteins.  These glycoproteins are necessary for 
the virus to bind CD4 and co-receptors.  The new copies can now move to infect 
other cells (Klatt, 2011; Kwong et al., 1998) 
 
2.6 HIV SUBTYPES 
 
HIV can be classified into two distinct types since there are two distinct species.  
HIV-1 and HIV-2 have been identified and each is composed of clades or 
multiple subtypes.  All clades of HIV-1 tend to cause similar disease, but the 
distribution of the clades differs (Bennett, 2011; Klatt, 2011).  HIV-1 is 
responsible for the worldwide pandemic of AIDS whereas HIV-2 is clustered 
prominently in West-Africa.  Although it is associated with AIDS in some cases, it 
is less virulent in its effects than HIV-1 (Klatt, 2011; Blattner, 1991). 
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There are several subtypes of HIV-1 which can be classified genotypically into 
several subtypes or clade groups on the basis of genotypic variation in the env 
region.  Infection with HIV-2 progresses more slowly to AIDS, and has a slightly 
lower risk of transmission.  This may be due to a less-aggressive infection rather 
than a specific property of the virus itself (Klatt, 2011).  HIV-2 tends to have a 
lower viral load than HIV-1.  The rapid progression to AIDS is associated with a 
greater viral load.  Since HIV-2 is rare in the developed world most research has 
been focused on HIV-1 (Bennett, 2011; Klatt, 2011). 
 
2.7 THE TYPICAL COURSE OF INFECTION 
 
The clinical features of HIV can be determined by a CD4 lymphocyte count.  
When the number of virus particles (viral load) rises during the course of the 
illness, the number of CD4 lymphocytes fall.  When the CD4 lymphocyte count 
falls below 350 cells per (/) cubic millimeter (mm3), the person becomes 
susceptible to infection (see Figure 2.5).  According to Klatt (2011) the majority of 
life threatening infections and tumors occur at CD4 counts below 200 cells/mm3. 
 
 
Figure 2.5: The Typical Course of HIV Infection (Bennett, 2011) 
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2.7.1 Primary Infection 
Two to six weeks after exposure to HIV, the majority of people develop transient, 
often mild, non-specific illnesses (sero-conversion or acute HIV syndrome).  This 
is caused by high circulating levels of HIV and a fall in the CD4 cell count.  The 
most common symptoms are: malaise, joint pain, a rash, muscle pain, mouth 
ulcers and sore throats.  Most of these symptoms resolve after seven to ten 
days.  In a few people the illness is more severe and may be associated with 
opportunistic infection, such as pneumonia, when the CD4 count falls below    
200 cells/mm3. 
 
2.7.2 Asymptomatic phase (CD4 count greater than 350cells/mm3) 
 
In this stage the CD4 cell count usually increases again, but still to a level below 
normal.  Although people with a CD4 cell count greater than 350cells/mm3, have 
enlarged lymph nodes, they are usually asymptomatic.  The length of the 
asymptomatic phase varies from person to person.  In most people it lasts six to 
eight years, in about five to ten percent of people it can last for many years and 
in others for decades.  However, in some people there is a rapid fall in the CD4 
cell count and progression to the symptomatic phase happens within six to 
twelve months. 
 
2.7.3 Symptomatic phase (CD4 count 200-350cells/mm3) 
 
With a CD4 cell count below 350cells/mm3, the person becomes increasingly 
susceptible to a number of infections.  These include: pulmonary tuberculosis, 
shingles, pneumoccocal pneumonia, recurrent oral and vaginal candidiasis and, 
although rarely, oral hairy leukoplakia.  Individuals also become more susceptible 
to Karposi’s sarcoma and lymphoma.  People may develop intermittent or 
persistent non-specific constitutional symptoms, which include: lethargy, 
anorexia, weight loss, diarrhoea, fever and night sweats. 
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2.7.4 Advanced phase (CD4 count less than 200cells/mm3 (AIDS) 
 
When the CD4 cell count continues to fall, opportunistic infections and HIV 
related tumors may develop.  It is said to be AIDS when a CD4 cell count is less 
than 200cells/mm3, and/or an AIDS defining condition is detected.  This is also 
referred to as Advanced HIV.  
 
2.8  TREATMENT 
 
2.8.1  Introduction  
 
At the very beginning of the AIDS epidemic, people living with HIV were deemed 
not likely to live more than a few years. With the development of safe and 
effective drugs, HIV-infected people now have longer and healthier lives.  There 
are no drugs to cure HIV infection but those that are available prevent the 
development of AIDS.  Not only do they stop the virus from being made in the 
body, they also ultimately stop the virus from damaging the immune system.  
Nevertheless, the fact remains that even these drugs cannot eliminate HIV from 
the body (WHO, 2009). 
 
The treatment for HIV, using anti-HIV drugs, is known as ART.  The standard 
treatment involves a combination of at least three drugs to be taken at any one 
time in order to suppress HIV replication.  These combination drugs are also 
known as “highly active antiretroviral therapy (HAART)”.  They are used to 
reduce the likelihood of the virus developing resistance.  ART has the potential to 
reduce mortality and morbidity rates among HIV-infected people, and to improve 
their quality of life (WHO, 2009). 
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With the introduction of combination antiretroviral therapy in 1996, the course of 
the disease in high-income countries has been altered for those already infected 
with HIV.  However, in low and middle-income countries only a fraction of the 
people living with HIV have access to this therapy, keeping in mind that the 
people in the low and middle-income provide for 90% of the global HIV burden 
(WHO, UNAIDS & UNICEF, 2011; Flanigan, Campbell, Harwell & Kumarasamy, 
2005).  
 
Although the use of combination ART has improved the course of the disease, 
this therapy is not universally available.  It should also be kept in mind that ART 
does not prevent the massive immune destruction that occurs soon after infection 
(Geise & Duerr, 2009; Brenchley et al., 2004) and it does not prevent the 
transmission of the virus (Geise & Duerr, 2009).  The treatment of HIV-infected 
people, with antiretroviral drugs and drugs for the prevention and treatment of 
opportunistic infections, benefits individuals, communities, and nations.  Support 
and effective care can enhance prevention by reducing stigma, increasing rates 
of HIV testing and possibly reducing transmission (Geise & Duerr, 2009).  Access 
to HIV health services, in many low and middle-income countries, is constrained 
by under-resourced health systems and many ART programmes are not well-
integrated with other health services (WHO, 2011).  In many poor countries, 
access to HIV health services is limited by fragile health systems.  Ten million 
people who are eligible do not have access to ART because of structural barriers 
such as discriminatory laws and outdated drug control policies.  This exacerbates 
inequities in accessing treatment (Hirnschall & Schwartländer, 2011).  According 
to Lockman (2011), breast milk will infect approximately 10%-15% of infants in 
the absence of ARV treatment.  This is still the case, even though, significant 
advances have been made in antiretroviral therapy since the introduction of 
zidovudine (AZT) in 1987 (Rathbun, 2011). 
 
 22 
The World Health Organization guidelines on ART were first published in 2002, 
with revisions in 2003, 2006, and 2010.  The 2010 guidelines reflect the evidence 
that the earlier ART is started (≤ 350 CD4 cells/mm3) the more cost effective it is, 
reducing HIV and tuberculosis transmission, and improving health outcomes 
(Hirnschall & Schwartländer, 2011; WHO, 2011 & 2009).  In 2003, WHO laid out 
a strategic rationale for the rapid scale-up of ART in low-income and middle-
income countries (Hirnschall & Schwartländer, 2011).  When WHO and UNAIDS 
launched the “3 by 5” initiative on World AIDS Day in 2003, only 400 000 people 
in low and middle-income countries had access to antiretroviral therapy (WHO, 
UNAIDS & UNICEF, 2011 & 2009).  HAART has nearly halved mortality among 
patients with AIDS and with it, the HIV-infection in patients who have access to 
medication and who achieve durable virologic suppression can now be managed 
like a chronic disease (Rathbun, 2011; Palella et al., 1998).   
 
High mortality rates remain five times higher in patients with AIDS than in HIV-
infected patients without AIDS.  Viral loads greater than 400 copies/mℓ 
(compared with < 400 copies/mℓ), and CD4 counts less than 200 cells/mm3 
(compared with > 200 cells/mm3) and cytomegalovirus retinits are the biggest risk 
factors for excessive mortality (Rathbun, 2011; Puhan et al., 2010).  The UNAIDS 
Secretariat and WHO launched the Treatment 2.0 initiative in June 2010.  It was 
designed to achieve and sustain universal access, to maximize the preventive 
benefits of antiretroviral therapy (ART), and also to dramatically improve the 
efficiency and impact of HIV care in resource-limited countries (WHO, UNAIDS & 
UNICEF, 2011; Hirnschall & Schwartländer, 2011; WHO, 2011). 
 
By the end of 2010 the number of people receiving antiretroviral therapy had 
increased to 6.65 million.  Effective antiretroviral regimens were given to almost 
50% of pregnant women living with HIV, to prevent MTCT.  That was an increase 
of over 1.4 million people, or 27% from December 2009.  The greatest increase 
of people receiving ART was in sub-Saharan Africa, increasing from 3 911 000 in 
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December 2009 to about 5 064 000 a year later (WHO, UNAIDS & UNICEF, 
2011).  In 2010, WHO recommended that antiretroviral therapy should be 
initiated with a CD4 cell count less than 350 cells/mm3, since clinical evidence 
shows that starting therapy that soon significantly reduced morbidity and 
mortality and also has significant benefits in preventing HIV infection (WHO, 
UNAIDS & UNICEF, 2011; WHO, 2010) (see Figure 2.6). 
 
With the provision of antiretroviral prophylaxis to pregnant women living with HIV, 
more than 350 000 children have been prevented from acquiring HIV-infection 
since 1995 (WHO, UNAIDS & UNICEF, 2011).  Regardless, for every person 
treated with ART four new people become infected (WHO, 2007) (see Figure 
2.7). 
 
Figure 2.6: Number of people with access to antiretroviral therapy and the 
number of people dying from AIDS-related causes, low- and middle-income 
countries, 2000-2010 (WHO, UNAIDS & UNICEF, 2011) 
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Figure 2.7: Coverage of antiretroviral prophylaxis for preventing the mother-to-
child-transmission of HIV and the number of new HIV infections among children, 
low- and middle-income countries, 2003-2010 (WHO, UNAIDS & UNICEF, 2011). 
 
2.8.2 How does ARV therapy work? 
 
The main aim of ARV therapy is to prevent the HI virus from multiplying inside a 
person.  This virus is very active, multiplying itself before damaging the body’s 
immune cells (CD4 cells).  It also adapts quickly to whatever medicines are being 
taken as it tries to mutate so that these medicines no longer work (WHO, 2009).  
If the virus’ growth stops, the body’s immune CD4 cells are able to live longer 
and provide the body with protection from infections. At the close of 2008, more 
than four million people in low and middle-income countries were receiving 
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antiretroviral therapy (WHO, 2009).  An additional 1.2 million received 
antiretroviral therapy in 2009, bringing the number of people receiving treatment 
to 5.2 million, a 30% increase (WHO, 2010). 
 
2.8.3 How do antiretroviral drugs work? 
 
As the HI virus multiplies inside an infected cell, it makes copies of itself that go 
on to infect other healthy cells within the body.  The more cells are infected, the 
greater the impact on the immune system, and the more severe the deficiency in 
the immune system (WHO, 2009).  Antiretroviral drugs interfere with the self 
copying of HIV and the way it spreads from cell to cell. There are several 
different classes of drugs that can be used (WHO, 2009). 
 
2.9  DRUG CLASSIFICATION 
 
There are currently six major classes of antiretroviral drugs: nucleoside drugs, 
nucleoside analogue reverse transcriptase inhibitors (NRTI’s), non-nucleoside 
reverse transcriptase inhibitors (NNRTI’s), protease inhibitors (PI’s), fusion 
inhibitors, chemokine co-receptor antagonists (consisting of 2 subclasses: the 
chemokine receptor 5 (CCR5) antagonist and CXC chemokine receptor 4 
(CXCR4) antagonist, and integrase inhibitors.  The ways in which the drugs work 
on HIV are shown in Figure 2.8. 
 
NRTIs: function by inhibiting the synthesis of DNA by reverse transcriptase, the 
viral enzyme that copies viral RNA into DNA in newly infected cells.  Nucleoside 
analogues bear the structural resemblance of the natural building blocks of DNA, 
known as nucleosides adenosine, guanosine, thymidine and cytidine.  They are 
triphosphorylated within the cell, and some undergo further modifications.  
Nucleoside analogues resemble monophosphorylated nucleosides, and therefore 
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require only two additional phosphorylations to become active inhibitors of DNA 
synthesis.  Reverse transcriptase fails to distinguish the phosphorylated NRTIs 
from their natural counterparts, and attempts to use the drugs in the synthesis of 
viral DNA.  When an NRTI is incorporated into a strand of DNA being 
synthesized, the addition of further nucleosides is prevented, and a full-length 
copy of the viral DNA is not produced.  See Figure 2.8 below: The mechanisms 
of drugs on HIV (Spach & Gallant, 2012). 
 
Figure 2.8: The mechanisms of drug inhibition on HIV (Spach & Gallant, 2012). 
 
NNRTIs: also inhibit the synthesis of the viral DNA, but rather than act as a false 
nucleosides, the NNRTIs bind to reverse transcriptase in a way that inhibits the 
enzyme’s activity (Klatt, 2011; Kwong et al., 1998). 
 
PIs: bind to the active site of the viral protease enzyme, preventing the 
processing of viral proteins into functional conformations.  Viral particles are still 
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produced when the protease is inhibited, but these particles are not infecting new 
cells (Klatt, 2011; Kwong et al., 1998). 
 
Fusion inhibitors: prevent HIV from entering the target cells.  Drugs of this class 
bind the HIV envelope glycoprotein 41 (gp41), which is involved in viral entry.  By 
blocking the interactions between regions of the gp41 molecule, fusion inhibitors 
interfere with the conformational change (folding) of the envelope molecule 
required for fusion with the target cell membrane (Klatt, 2011; Kwong et al., 
1998).  
 
Chemokine co-receptor antagonists: prevent the entry of HIV into target cells.  
They bind to co-receptors (either CCR5 or CXCR4) on the surface of CD4 cells.  
By so doing, they block a required step in viral entry.  Co-receptor antagonists 
bind human proteins (Klatt, 2011; Kwong et al., 1998). 
Integrase inhibitors: bind a viral enzyme known as integrase and interfere with 
the incorporation of reverse-transcribed HIV DNA into the chromosomes of host 
cells (Klatt, 2011; Kwong et al., 1998). 
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2.10 BREASTFEEDING 
 
2.10.1 Introduction 
 
Lactation is the medical term for breastfeeding, a natural method of feeding an 
infant from birth to the time he or she can eat solid food.  The saying that "breast 
is the best" has its origin in biologic merit and several studies have confirmed that 
even economically deprived and undernourished women have adequate breast 
milk, similar in quality to milk produced by well-nourished women (Leung & 
Sauve, 2005; Kramer, 2010). UNICEF declared breastfeeding the superior 
choice, both physically and economically and many experts see mother’s milk as 
the ultimate health food.  UNICEF (2012), not only views breast milk as the best 
food for newborn babies but also as the only food they need, hence the American 
Academy of Pediatrics recommends that babies be breastfed at least for six to 
twelve months.  
 
Breastfeeding exclusively means that an infant receives only breast milk from his 
or her mother and no other liquids or solids , not even water, with the exception 
of oral rehydration solution, drops or syrups consisting of vitamins, mineral 
supplements or medicines (WHO, 2003).  For optimal growth and development, 
infants should be exclusively breastfed for the first six months of life (Campbell, 
2008), breastfeeding initiated as soon after delivery as possible (UNICEF, 2012; 
Leung & Sauve, 2005) since nutrition is crucial for newborn babies.  The best 
source of that nutrition, according to just about every medical source, is breast 
milk (Champbell, 2008).   
 
Adequate nutrition is the main aim of infant feeding. A baby’s growth is more 
rapid during the first six months than at any other time in its life. Babies double 
their birth weight in and around four months and have tripled it by the age of one 
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year. All parts of the body develop quickly and gain tremendously in size.  The 
baby’s nutritional needs run parallel with its growth (Bartok, 2011).  However, 
malnutrition has been responsible, directly or indirectly, for 60% of the 10.9 
million deaths annually among children under the age of five (Champbell, 2008).  
The Bellagio Child Survival Group research evidence states that infants aged 0-5 
months, not breastfed, had seven-fold and five-fold increased risks of death from 
diarrhoea and pneumonia respectively, compared with infants who were 
exclusively breastfed (Doherty et al., 2010).  At the same age, non-exclusive 
rather than exclusive breastfeeding resulted in a more than two-fold increased 
risk of dying from diarrhoea and pneumonia according to Doherty et al. (2010). 
 
Exclusive breastfeeding is the most effective intervention to save the lives of 
millions of children in developing countries.  If exclusive breastfeeding for infants 
younger than six months could universally be increased by 90%, approximately 
1.3 million child deaths per year would be prevented (Doherty et al., 2010; 
Sadoh, Sadoh, Adeniran & Abhulimhen-Iyoha, 2008).  Studies from developing 
countries showed that infants who were not breastfed were six to ten times more 
likely to die in the first few months of life than infants who were breastfed.  
Pneumonia and diarrhoea were also more common and more severe in children 
who were not breastfed (WHO, 2003).  Thus, adequate nutrition during infancy 
and early childhood is essential to ensure the growth, health and development of 
children to their full potential.  It is said that one third of the estimated 9.5 million 
deaths that occurred in 2006 in children younger than five were because of poor 
nutrition (WHO, 2009; WHO, 2003). 
 
Optimal infant and young child feeding practices are among the most effective 
interventions to improve child health.  At least 35% of child deaths are associated 
with under-nutrition (WHO, 2003) with one in seven children in sub-Saharan 
Africa having died before their fifth birthday in 2008.  This region accounted for 
half the child deaths worldwide for the same period and is the region with the 
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highest mortality rate in children under the age of five.  Across all regions of the 
developing world, children from poorer households remain disproportionately 
vulnerable.  In developing countries most children continue to die from 
preventable or treatable causes, pneumonia and diarrhoea the two main killers.  
Undernutrition contributes to more than a third of all deaths of under-fives (see 
Figure 2.9 UNICEF, 2012). 
Neonatal 41%
Others 16%
Measels 1%
HIV/AIDS 2%
Injuries 3%
Malaria 8%
Diarrhoea 14%
Pneumonia 14%
 
 
 
2.10.2 Breast milk composition 
 
The first food most humans encounter is breast milk, which serves as the sole 
source of all nutrients required for biological functions and growth during the 
early stages of life. It is considered the optimal method of infant feeding (Leung & 
Sauve, 2005). 
 
Globally, more 
than one third 
of child deaths 
are attributable 
to 
undernutrition 
Figure 2.9: Causes of under-five deaths in 2008 
 
Adapted from: UNICEF, 2012. 
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Colostrum is the special milk that is secreted in the first two to three days after 
delivery. It is produced in small amounts (40-50mℓ) on the first day.  At that time it 
is all that a baby needs (WHO, 2003).  Between the third and sixth day of 
lactation, the colostrums starts to change to milk, a process completed by the 
tenth day.  This mature milk, thin and bluish in color like skim milk, has an ideal 
nutrient composition for the infant (Georgeson & Filteau, 2000).  Colostrum is rich 
in antibodies and white blood cells, especially secretory immunoglobulin A (sIgA), 
and it contains a large amount of proteins, minerals and fat-soluble vitamins 
(vitamin A, E and K), more so than later milk.  Colostrum provides immune 
protection against micro-organisms in the environment upon first exposure 
(WHO, 2003). 
 
Breast milk is a species-specific liquid and contains unique substances such as 
living cells (e.g., macrophages), hormones, antibodies (e.g. immunoglobulins 
such as IgA), active enzymes (which promote gut maturation, facilitate digestion 
and stimulate passage of meconium) and other proteins that cannot be artificially 
supplied to the infant.  It serves both a nutritive and immunological function 
essential for survival (Wagner, 2012).  Nutrients that an infant needs in the first 6 
months of life are found in breast milk, including fat, carbohydrates, proteins, 
vitamins, minerals and water.  These nutrients are easily digested and efficiently 
used. Breast milk also contains factors that help with digestion and the 
absorption of nutrients as well as bioactive factors which augment the infant’s 
immature immune system by providing protection against infection (WHO, 2003).  
 
Humans do not need specific foods for survival; rather, they need the 
components of food, called nutrients.  These nutrients are grouped into six 
general classes: carbohydrates, fats, proteins, vitamins, minerals, and water, 
which will be discussed in the following paragraph:   
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2.10.2.1 Fat 
Fat provides about one half of the energy content of breast milk.  It is secreted in 
small droplets and the amount increases as the feeding progresses.  The 
hindmilk secreted towards the end of a feed is rich in fat, while the foremilk at the 
beginning of a feed contains less fat.  The fat in breast milk contains long chain 
polyunsaturated fatty acids (docosahexaenoic acid or DHA, and arachidonic acid 
or ARA) which play an important role in the neurological development of the baby 
and are not available in other milk (WHO, 2003). 
 
2.10.2.2 Carbohydrates 
 
Milk sugar lactose, a disaccharide, is the main carbohydrate in breast milk.  It is 
an important source of energy.  Oligosaccharides, or sugar chains, are another 
kind of carbohydrate present in breast milk and play an important role in the 
protection against infection (WHO, 2003). 
 
2.10.2.3 Protein 
 
The protein in breast milk differs in quantity and quality from proteins in animal 
milk.  Breast milk protein contains a balance of amino acids which makes it much 
more suitable for babies (WHO, 2003). 
 
2.10.2.4 Vitamins and Minerals 
 
Unless a mother herself is deficient, breast milk normally contains sufficient 
vitamins for the infant.  Vitamin D is the exception and the infant needs exposure 
to sunlight to generate endogenous vitamin D, or if this is not possible, a 
supplement.  The minerals, iron and zinc, are present in breast milk in relatively 
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low concentrations and their bioavailability and absorption is high.  If a mother’s 
iron store is adequate, term infants are born with a store of iron to supply all their 
needs.  Vitamin A plays an important role in the protection of the eyes and for the 
integrity of the epithelial surfaces (WHO, 2003) 
 
2.10.2.5 Anti-infective factors 
 
There are many factors in breast milk which help to protect an infant against 
infections: 
 sIgA – prevents bacteria from entering the cells by coating the intestinal 
mucosa; 
 White blood cells – can kill micro-organisms; 
 Whey proteins (lysozyme and lactoferrin) – can kill bacteria, viruses and 
fungi; 
 Oligosaccharides – prevents bacteria from attaching to mucosal surfaces 
(WHO, 2003). 
 
The protection provided by these factors is uniquely valuable for the infant since 
it occurs without causing the effects of inflammation, such as fever, which can be 
dangerous for a young infant.  The mother’s body forms sIgA which contains 
antibodies against bacteria and other infections she may have encountered.  
These automatically protect the baby against bacteria that are particularly likely 
to be in the baby’s environment (WHO, 2003; Georgeson & Filteau, 2000). 
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2.10.2.6 Other bioactive factors: 
 
Breast milk also contains the following: 
 Bile-salt stimulated lipase – digests the fat completely once the milk has 
reached the small intestine.  In artificial milk the fats are digested less; 
 Epidermal growth factor – stimulates the maturation of the lining of the infant’s 
intestine.  This enhances the digestion and absorption of nutrients, and is less 
easily infected or sensitized to foreign proteins; 
 Other growth factors – the developing and maturation of nerves and the retina 
(WHO, 2003). 
 
2.10.3 Breastfeeding versus Formula feeding 
 
In resource-poor regions of the world where unhygienic settings and very little 
financial income prevail, breastfeeding is of particular importance.  According to 
Leung & Sauve (2005), economically breastfeeding is less expensive than 
formula feeding.  Studies have also shown health benefits in that mothers who 
are poor and HIV-positive, but exclusively breastfeed their infants have a lower 
risk of infecting the infants with HIV than those who are partially breastfed or who 
receive mixed feeding (Buskens, Jaffe & Mkhatshwa, 2007; Iliff et al., 2005).  
 
For the vast majority of women in these regions the avoidance of breastfeeding is 
not a realistic option.  Studies have shown that even after counselling on feeding 
choices, HIV-infected women chose to breastfeed their babies, causing one to 
wonder whether this choice was made through freedom or necessity (Coutsoudis 
et al., 2001). 
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2.10.4 Factors affecting successful formula feeding: 
 
 Access to a steady, sustainable supply of the feed 
 Availability of clean water to prepare the feed 
 Access to basic sanitation facilities 
 Availability of fuel to prepare the feed 
 The mother’s health 
 Local community infant feeding norms and levels of stigma surrounding 
replacement feeding 
 The mother’s ability and willingness to disclose her HIV status to her partner 
and family (Campbell, 2008; Sadoh et al., 2008) 
 
2.10.5 Advantages of breastfeeding for mothers 
 
Advantages for mothers who breastfeed, include the following: early involution of 
the uterus, enhanced bonding between mother and child, lactation amenorrhea, 
and the reduction incidence of ovarian and breast cancer (Leung & Sauve, 
2005).  It is also labour saving since the milk is at the right temperature, and 
there is no risk of contamination with pathogens.  It develops the mother-baby 
relationship and gives the baby a feeling of security and is the safest way to feed 
an infant (Leung & Sauve, 2005).   
 
2.10.6 Advantages of breastfeeding for the infant 
 
Breastfeeding can reduce the incidence and severity of infections since the 
mother’s milk contains and provides natural defenses, prevents allergies, obesity 
and hypertension and insulin-dependent diabetes mellitus and enhances 
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cognitive development (Leung & Sauve, 2005).  The incidence of infection, 
especially enteral infection, has been found to be higher in artificially fed than in 
breast fed babies, even in highly developed communities.  Breastfeeding, 
therefore, is generally associated with significantly decreased infant morbidity 
and mortality rates (Leung & Sauve, 2005). 
 
2.11 HIV AND BREASTFEEDING 
 
2.11.1 Background 
 
The greatest biomedical challenge of this century is HIV-1 infection leading to 
AIDS.  This disease has been devastating because of its concentration in young 
adults, thus affecting social stability from the level of individual families to 
national economies since an estimated 33 million people worldwide are infected 
with HIV (Kourtis, Bulterys, Hu & Jamieson, 2012).  HIV, unfortunately, among 
other diseases may be transferred to the infant through breast milk.  There is a 
continuing debate among developed and developing populations in the world 
about the breastfeeding of infants born to HIV-infected mothers (Shearer, 2008) 
with studies having shown that the transmission risk (in percentage) of HIV 
through breastfeeding may vary between four and nineteen percent.  
Breastfeeding is responsible for 40% of all MTCT of HIV (Lockman, 2011) and 
HIV transmission specifically occurs through the cell-rich colostrum fraction of 
breast milk (Shearer, 2008). 
 
Risk of transmission of HIV from mother to the child is considered to be at its 
highest during breastfeeding, the breast milk itself serving as a vector of HIV 
transmission.  The first case of MTCT of HIV, with breast milk as the expected 
carrier, was reported in 1985 (Humphrey & Iliff, 2001).  Only then was it shown 
that the virus was present in breast milk and could reach concentrations 
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adequate for transmission (Rousseau et al., 2003).  Of the estimated 3.6 million 
children then infected with HIV, 1.2 to 1.8 million were infected through 
breastfeeding.  
 
Women in developing countries have the difficult choice of balancing the risk of 
transmitting HIV through breast milk against the substantial benefits of 
breastfeeding.  However, it is questionable whether the benefits of breastfeeding 
when the mother is HIV-infected can be compared to the benefits when the 
mother is not HIV-infected, especially in terms of nutrient content.  A dangerous 
situation therefore arises, especially in poor developing environments, with HIV 
infected mothers being considered as a risk for transmitting HIV to their infant via 
breast milk, and on the other hand, the risk of infection with deadly microbial 
contaminants in bottle feeding preparations.  HIV-infected populations are 
burdened with malnutrition and numerous studies have reported that these 
deficiencies impair immune responses and are associated with accelerated HIV 
disease progression (Dreyfuss & Fawzi, 2002).  As a result, WHO, UNICEF and 
UNAIDS have adapted infant feeding options for HIV-infected women and now 
support the possibility that an HIV-infected woman informed of her HIV-positive 
status will choose the safest feeding option.  They recommend that HIV-infected 
women who decide not to breastfeed their children must be ensured access to 
sufficient quantities of nutritionally adequate breast-milk substitutes they can 
prepare safely (Dabis et al., 2000).   
 
According to Lockman (2011), WHO released revised guidelines on infant 
feeding by HIV-infected mothers in low and middle-income settings in July 2010. 
These guidelines take into account that factors such as cost, lack of access to 
clean water, refrigeration, materials for boiling water and stigma, do not make 
formula feeding in developing countries feasible.  Also, in low and middle-income 
countries replacement feeding is being associated with high rates of infant 
morbidity and mortality related to pneumonia, diarrhea, and other illnesses, 
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making the avoidance of breastfeeding very risky (Lockman, 2011). The risks 
and benefits must be weighed when deciding on a feeding option, in fact, the first 
principle must be a feeding option to optimize the health of the HIV-exposed 
baby (Lockman, 2011).  
 
Exclusive breastfeeding for the first six months of life, and continued 
breastfeeding after that for some undetermined duration, will provide the greatest 
chance of infection-free survival (Shearer, 2008; Humphrey, 2010) since 
exclusive breastfeeding during the first few months of life carries a lower risk of 
HIV transmission than mixed feeding.  Seeing that breast milk is the natural, not 
a lifestyle choice, for the poor it becomes the difference between life and death 
for mothers and babies in developing countries (Coovadia, Rollins, Bland, Little, 
Bennish & Newell, 2007; WHO, 2003). 
 
2.12 MOTHER-TO-CHILD TRANSMISSION OF HIV 
 
The first description of AIDS in children and the possible transmission from 
mother to child were first published in the early 1980s (McIntyre & Gray, 2009; 
Oleske et al., 1983; Cowan et al., 1984).  Breast-milk transmission accounts for 
up to half of the global HIV infections in children (John-Stewart, 2007).  
Prolonged breastfeeding in developing countries is common and MTCT of HIV 
remains considerable, accounting for forty two percent of HIV infections in infants 
and young children in Africa (Buskens et al., 2007). 
 
Although the exact mechanism of transmission from breast milk is not fully 
understood, it is thought that exposure to microbes in water and food may cause 
micro-trauma to infants’ bowels, which provides an entry point for HIV 
transmission (Buskens et al., 2007).  Infection can occur through the entry of cell-
free HIV virions or of cell-associated HIV.  Both forms of HIV have been detected 
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in colostrums and breast milk although the viral load in breast milk proved lower 
than in plasma (Walter, Kuhn & Aldrovandi, 2008; Lehman & Farquhar, 2007; 
Rousseau et al., 2003).  The cell-associated virus correlates with the risk of early 
transmission and both, cell-associated and cell-free, with later transmission 
(Koulinska et al., 2006).  The cell-free virus could penetrate the mucosal lining of 
the gastro-intestinal tract of infants.  The virus then infects the inter-epithelial 
dendritic cells and can be sampled by M cells of the Peyer’s patches.  It can also 
enter the submucosa directly through the mechanisms which allow intact proteins 
to transverse the immature mucosal barrier.  Another entry point could be 
through damaged mucosal foci.  These mucosal factors may explain the 
protective effect of exclusive breastfeeding over mixed feeding, which has been 
documented in several studies (Kuhn et al., 2007; Iliff et al., 2005; Coutsoudis et 
al., 2001).  
 
Although antiretrovirals suppress the cell-free they do not do so for the cell-
associated virus (Shapiro et al., 2005). Nevertheless, the risk of MTCT can still 
be reduced by antiretroviral strategies.  This will necessitate balancing the risk of 
morbidity and mortality caused by replacement feeding in low resource settings 
(McIntyre & Gray, 2009) since the comparative risk of death in the first two 
months of life from other infectious diseases, especially diarrhoea, is six-fold 
greater in formula-fed children than breastfed children in developing countries 
(Buskens et al., 2007; Coutsoudis et al., 2001). 
 
The South African Department of Health and the National AIDS Council released 
revised guidelines for the prevention of MTCT of HIV in April 2010, stating that all 
HIV-infected pregnant women with CD4 cell counts of ≤ 350 cells/mm3 should 
receive HAART.  HIV-exposed infants whose mothers are not on HAART should 
receive six weeks of ARV prophylaxis and nevirapine with continued prophylaxis 
until one week after complete cessation of breastfeeding and all confirmed HIV-
positive infants should receive HAART from as early as six weeks of age.  These 
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guidelines also state that the approach to infant feeding should not only be to 
avoid HIV transmission, but also to maximize child survival (Doherty et al., 2010).  
If ART is administered to mothers during pregnancy and intrapartum and to the 
infant in the neonatal period it could reduce the overall risk of vertical 
transmission of HIV-1 to approximately eight percent.  ART regimens in 
resource-poor settings have also resulted in the reductions of MTCT of HIV-1 by 
33% to 50% (Newell, 2005; Dabis et al., 2000). 
 
Breastfeeding adds to the risk of vertical transmission of HIV-1, especially in 
infants who are fed a combination of breast milk and other liquids and solids.  An 
estimated 1.5 million children infected with HIV were living in the world at the end 
of the twentieth century.  An additional 500 000 to 600 000 infants were acquiring 
infections each year from their mothers, the majority living in sub-Saharan Arica.  
Women now account for nearly half of the five million or so incident infections in 
adults and with most of them are in their childbearing years, they  transmit the 
infection to their children at a rate of approximately 1500 cases per day (Newell, 
2005; Dabis et al., 2000). 
 
The most overwhelming source of HIV-1 infection in young children is caused by 
MTCT.  Despite effective antiretroviral therapy, there were approximately 700 
000 new infections in children worldwide in the year 2003, according to WHO. 
The majority of these infections were reported from resource-limited countries 
(Newell, 2005; Scarlatti., 2004).  In 2005, an estimated 630 000 – 820 000 infants 
were newly infected, 280 000 – 360 000 would have been infected through 
breastfeeding (Coovadia et al., 2007; Newell, 2005).  An estimated 1.49 million 
pregnant women in low and middle-income countries were living with HIV in 
2010.  Seventy five percent of these pregnant women were concentrated in ten 
countries, amongst them Kenya, Mozambique, Nigeria and South Africa 
(UNICEF, 2012). 
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An HIV infected mother can pass HIV to her unborn baby at any of the following 
3 stages: 
 During pregnancy: accounts for 15-20% of MTCT cases. 
 During delivery: is responsible for the bulk of infections in children as 60-
70% of infections happen at this stage. 
 Breastfeeding is one of the ways HIV gets passed from mother to child, 
accounting for 15-20% of infections (UNICEF, 2012).  
 
2.12.1 Potential factors affecting mother-to-child HIV transmission include 
The following potential factors affecting MTCT include: 
 The pattern of breastfeeding (babies who are breastfed may have a lower risk 
of becoming infected than those who also consume other liquids, milks, or 
solid foods in the first months of life) (Coutsoudis et al., 2001) 
 Breast health (mastitis, cracked and bloody nipples, and or other indications 
of breast inflammation are associated with higher risks of transmission) 
 Breastfeeding duration 
 Maternal viral load (which is higher with recent infection or advanced disease 
in the mother) 
 Maternal immune status, CD4 cell counts 
 Maternal nutritional status (Campbell, 2008; Newell, 2005) 
 Mode of delivery 
 Time of rupture of membranes to delivery 
 Prematurity 
 Infant birth weight (Newell, 2005) 
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2.13 WHO GUIDELINES ON HIV AND INFANT FEEDING 2010 
 
World Health Organization guidelines of 2010 on HIV and infant feeding state 
that the risk of postnatal transmission of HIV through breastfeeding can be 
reduced with ARV interventions, to either the HIV-infected mother or HIV-
exposed infant.  This has implications for how women living with HIV might feed 
their infants.  The breastfeeding and ARV intervention can significantly improve 
infants’ chances of surviving.  
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3.1 STUDY DESIGN AND WORKPLAN 
 
This study used a descriptive design.  Breast milk of HIV seronegative and HIV 
seropositive women was measured for nutrient composition.  Respondents were all 
volunteer lodging or day visitors at the Pediatric/Neonatal wards of hospitals and 
healthcare clinics in the Bloemfontein area: National, Pelonomi and Universitas 
Hospitals as well as Heidedal, Botshabelo and the Mangaung University of The 
Free State Community Partnership Programme (MUCPP) clinics.  
 
The breast milk and blood samples were obtained from the volunteers themselves 
and their clinical data was obtained from their patient files, if available, after 
permission was granted by the appropriate authorities.  Laboratory procedures and 
measurements were performed by the laboratory of Mowbray Maternity Hospital 
Milk Depot in Cape Town and the Pathcare Laboratory in Bloemfontein.  Below is a 
summarized layout of the data collection (Figure 3.1). 
 
 
 
  NUTRITIONAL COMPOSITION OF BREAST MILK 
30 HIV-non infected women 
(Control group) 
 
30 HIV-infected women 
not on treatment 
Consent form 
Demographic profile 
CD4 cell count 
Full blood count 
Milk analysis 
Consent form 
Demographic profile 
CD4 cell count 
Full blood count 
Milk analysis 
CHAPTER 3 
 
METHODS 
 
 
Figure 3.1 Summary lay out of the data collection 
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3.2 ETHICAL APPROVAL 
 
Approval for the study was obtained from the Ethics Committee of the University 
of the Free State (ETOVS 107/08).  The patients understood that they could 
withdraw from the study without having to explain their reasons for doing so.  
After their roles in the study were explained to each participant and they signed 
an informed consent form. 
 
3.3 POPULATION 
 
 
Two groups of female volunteers, from the same socio-economic background, 
were chosen to participate in this study.  Participation was voluntary, from 
lodging or day visiting mothers at the Pediatric/Neonatal wards of the following 
hospitals in the Bloemfontein area: National, Pelonomi, Universitas as well as 
clinics in Heidedal, Botshabelo and MUCPP.  Volunteers, who met the inclusion 
criteria and had given written consent, were selected after a screening visit. 
 
3.4 SAMPLE SIZE 
 
The first group consisted of 30 healthy, lactating HIV-non infected women, who 
represented the control group. The second group consisted of 30 lactating HIV-
infected women not on treatment. 
 
 
3.5 INCLUSION / EXCLUSION CRITERIA 
 
The criteria were set to ensure a homogeneous subject population with 
accompanying diseases.  The 60 respondents who were selected had to meet all 
inclusion criteria and none of the exclusion criteria and had to have given written 
consent. 
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3.5.1 Inclusion Criteria 
 
 All lactating women who exclusively breastfed. 
 Respondents had to at least be five days postpartum to avoid the analysis of 
colostrums as the analysis had to be performed on mature milk.  Colostrum is 
the deep yellow-colored milk secreted the first days after childbirth and its 
secretion lasts for about five days after birth.  It changes to mature milk 
gradually. 
 Respondents must not be breastfeeding for longer than 45 days. 
 Respondents had to be between 18-40 years of age. 
 Mothers should not been breastfeeding a previous child 
 
 
3.5.2 Exclusion Criteria 
 
 
 Evidence of psychiatric disorder, antagonistic personality, poor motivation to 
participate in this study or non-compliance with protocol requirements. 
 History of or current compulsive alcohol abuse (more than 10 drinks weekly) 
and/or regular exposure to other substance abuse. 
 Participation in another study with an experimental drug within eight weeks of 
the first administration of the study medication. 
 Heavy smoking (i.e. more than twenty cigarettes per day). 
 Diabetic HIV-positive individuals. 
 
 
3.6 WITHDRAWAL CRITERIA 
 
Although none of the volunteers withdrew, they had the right to withdraw from the 
study at any time, no matter what the reason. 
 
 
 
 46 
3.7 RESPONDENT IDENTIFICATION 
 
Each respondent received a number (01-60) and retained this number 
throughout the study. The participants’ initials and date of birth were obtained 
from a copy of their identification book. 
 
3.8 RESPONDENT INFORMED CONSENT 
 
After the respondents met the inclusion criteria, they were informed verbally and 
in writing about the nature of the study.  The purpose and the possible risks in 
taking part in this study were also explained verbally and in writing.  In order to 
facilitate understanding and provide respondents with adequate information, both 
the written information regarding the respondents and informed consent 
discussions were included.  After verbal consent to participate in the study was 
given by the volunteer respondents and they had accepted the terms of the 
study, they signed and dated the informed consent form.  The person who 
explained and conducted the informed consent discussion also signed with the 
respondents that they had accepted the terms and understood everything. 
 
The respondent information sheets and the informed consent forms were made 
available in English, Afrikaans and Sesotho (the indigenous language of the 
region).  Respondents were given a copy of both the information sheet and 
informed consent form in their choice of language. 
 
 
3.9 SAMPLE COLLECTION 
 
3.9.1 Questionnaire 
 
After the respondents consented to participate in the study, they were 
interviewed and asked to complete a questionnaire (Appendix A). 
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3.9.2 Breast milk samples 
 
Breast milk samples were collected just before the mothers started 
breastfeeding.  Participants were asked to abstain from breastfeeding their 
babies for three hours while the procedure was explained to each participating 
mother and they were asked to take the sample themselves.  Five mℓ of breast 
milk was collected from each participant in sterile (50mℓ) plastic containers. 
 
 
3.9.3 Blood samples 
 
Two 5mℓ EDTA tubes of blood were collected from each respondent by a 
registered medical nurse. 
 
 
3.9.4 Data from patient files 
 
The patients’ medical history, current treatment regimes, as well as their CD4 
count were obtained from their medical files, if and where available. 
 
 
3.10 LABORATORY PROCEDURES 
 
3.10.1 Sample Preparation 
 
3.10.1.1 Breast milk samples 
 
After the breast milk samples were collected in 50mℓ sterile plastic containers, 
the milk was divided into two separate sterile containers. This was done to 
ensure a homogenous sample. The milk was frozen for analysis and then sent to 
two different laboratories (Pathcare in Bloemfontein and Mowbray Maternity 
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Hospital Milk Depot in Cape Town).  The samples were transported, within two 
weeks of sampling, to Cape Town on dry ice to ensure that they stayed frozen 
until analyses could be done.  The refrigerated milk was defrosted under a 
stream of warm tap water for the analysis. 
 
3.10.1.2 Blood samples 
 
Blood samples (2 x 5mℓ EDTA tubes) were collected from each respondent by a 
registered medical nurse.  The samples were sent to Pathcare pathology 
laboratory for analysis.  All blood samples were processed according to the SOP 
of Pathcare.  Upon arrival at the laboratory, a full blood count (FBC) and CD4 cell 
count was done.  The EDTA tubes for the viral load count analysis were sent to 
Pathcare, Cape Town. 
 
 
3.11 BLOOD ANALYSIS 
 
The following procedures were performed on the blood samples: FBC and CD4 
cell counts. 
 
3.11.1 Full blood count 
 
Methodology of the test    
 
The EDTA tubes containing the patients’ blood were shaken for a few seconds to 
allow for proper mixing before being checked for clots with applicator sticks. 
 
A Sysmex® XT-2000i analyzer was used for the analysis of the FBC.  The 
Sysmex® XT-2000i is an automated heamatology analyzer for in vitro diagnostic 
use in clinical laboratories.  The Sysmex® XT-2000i performs analysis of the 
white blood cells (WBC) and reticulocytes with an optical detector block based on 
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the flow cytometry method, using a semiconductor laser.  RBC and platelet (Plt) 
counts were analyzed by the red blood cell detector using the Hydro Dynamic 
Focusing method.  Hemoglobin was analyzed by the hemoglobin detector based 
on the sulsolyser (SLS) hemoglobin detection method.  The Hct saw to the direct 
measurement of the red cell transducer.  The MCV, MCH and the mean 
corpuscular hemoglobin concentration (MCHC) are parameters calculated from 
the red cell parameters. 
 
Quality assurance  
Three levels of commercial controls were used for quality assurance: e-Checks 
1, 2 and 3. 
 
3.11.2 CD4 cell count 
 
Methodology of the test  
 
All reagents and controls were put on benches to reach room temperature.  The 
EDTA tubes containing the patients’ blood samples were vortexed for a few 
seconds to allow for the proper mixing of the samples.  The samples were then 
checked for clots with applicator sticks.  Twenty μℓ of MultiTEST 
CD3/CD8/CD45/CD4 (catalog nr 342417) reagent was pipetted from the bottom 
of a TruCOUNT Tube (catalog nr 342447).  Fifty μℓ of the patients’ blood was 
added to the bottom of the TruCOUNT tube.  The tube was vortexed, gently but 
thoroughly to allow for the proper mixing of the reagent and the EDTA blood.  
Afterwards, samples were incubated for 15 minutes in the dark, at room 
temperature.  Four hundred and fifty μℓ FACS Lysing solution (catalog nr 349202) 
was added to the tube after incubation, before it was vortexed again.  The tubes 
were incubated in the dark for 15 minutes and samples analyzed on the BD 
FACSCalibur analyzer (manufactured by Beckton Dickenson).  Flow cytometry 
was used to determine the CD4-, CD3- and CD8 positive cells.  The CD4 cell 
count was done to determine the immunological status of the patient.  It is an 
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essential measure for the risk of contracting opportunistic infections and is thus 
used as an indicator for instituting disease prophylaxis. 
 
Quality assurance  
 
The same procedure was repeated with the Trucount controls, in which low, 
MultiTEST 4-colour reagents use a time-saving lyse/no wash method for direct 
immunoflourenscence staining of human peripheral blood specimens.  When 
whole blood is added to TruCOUNT tubes containg MultiTEST reagents, the 
fluorochrome-labelled antibodies bind specifically to antigens on the surface of 
the lymphocytes.  The FACSCalibur flow cytometer detects four fluorescent 
colours as well as forward scatter and side scatter. 
 
 
3.11.3 Viral load 
 
The viral load measures and determines the quantification of HIV.  This is the 
test for staging HIV disease, and monitoring the efficiency of the treatment.  The 
viral load count was analyzed using the COBAS AmpliPrep and the Cobas 
TaqMan HIV-1 Test, both manufactured by COBAS.  This is a nucleic acid 
amplification test for the quantification of HIV Type 1 RNA in human plasma.  It 
uses the COBAS AmpliPrep instrument for automated specimen processing and 
the COBAS Taqman analyzer for automated amplification and detection. 
 
Methodology of the test 
 
The COBAS AmpliPrep/COBAS Taqman HIV-1 test is based on three major 
processes: 
 specimen preparation to isolate HIV-1 RNA; 
 reverse transcription of the target RNA to generate complementary DNA; 
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 simultaneous polymerase chain reaction (PCR) amplification of target 
complementary DNA and detection of cleaved dual-labelled 
oligonucleotide detection probe specific for the test. 
 
Automated specimen preparations were done by the COBAS AmpliPrep/Cobra 
TaqMan HIV-1.  This step was followed by automated reverse transcription and 
the PCR amplification and detection of HIV-1 target RNA and HIV-1 
Quantification Standard (QS) Armoured RNA.  The Master Mix was developed to 
ensure comparable quantification of group M subtype of HIV-1 and the Master 
Mix reagent contained a primer pair, specific for both HIV-1 RNA and HIV-1 QS 
RNA.  A target-specific and QS-specific dual-labelled oligonucleotide probe was 
used for the detection of amplified DNA.  This probe permitted independent 
identification of HIV-1 and HIV-1 QS amplicons.  
 
The HIV-1 QS is used for the quantitation of HIV-1 viral RNA.  It is a non-
infectious Armored RNA construct and contains HIV sequences with identical 
primer binding sites to the HIV-1 RNA target and a unique probe binding region.  
The HIV-1 QS was added to each specimen, at a known copy number, and was 
carried through specimen preparation, reverse transcription, PCR amplification 
and detection of cleaved dual-labelled oligonucleotide detection probes.  The 
HIV-1 RNA concentrations were calculated by the COBAS TaqMan analyzer by 
comparing the HIV-1 signal to the HIV-1 QS signal for each specimen and 
control.  Accurate quantifications of HIV-1 RNA in each specimen were allowed 
by the HIV-1 QS, which compensated for effects of inhibition and controlled the 
preparation and amplification processes.  Selection of the target RNA sequence 
for HIV-1 depended on identification of regions within the HIV-1 genome that 
showed maximum sequence conservation among the various HIV-1 groups M 
subtypes and HIV-1 group O specimens.  Two regions of the HIV genome were 
simultaneously targeted for amplification and detection by the COBRAS 
AmpliPrep/Cobas TaqMan HIV-1 Test in order to address the high genetic 
variability of the virus.  Two target-specific and one QS-specific dual-labelled 
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oligonucleotide probes allowed for independent identification of the HIV-1 
amplicon and of the HIV-1 QS amplicon. The selection of the primers and the 
dual-labelled oligonucleotide probes was critical for the ability of the test to 
amplify and detect the HIV-1 group M subtypes and HIV-1 group O.  The COBAS 
AmpliPrep/Cobas TaqMan HIV-1 test used reverse transcription and PCR 
amplification primers that defined sequences within the highly conserved regions 
of the HIV-1 gag gene and of the HIV-1 LTR region.  This test could quantitate 
HIV-1 RNA over the range of 40 – 10 000 000 copies/mℓ.  Qualified medical 
technologists/technicians performed the viral load testing as per Pathcare 
Laboratory’s SOP for viral load testing.  
 
Quality assurance  
HIV-1 L (+) C, HIV-1 H (+) C and CTM (-) C 
 
 
3.12 BREAST MILK ANALYSIS 
 
Each laboratory’s standard operating procedures were followed for the analysis 
of the biochemical variables in the breast milk.  The following variables were 
included in the analysis of the breast milk.  
 
Macro-nutrients: Protein (%); 
 Lactose (%); 
Micro-nutrients: Calcium (mmol/ℓ); 
 Phosphate (mmol/ℓ). 
 
Other: Fat (%); 
 Energy (kcal/100mℓ) 
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Proteins, lactose and fat were analyzed at the Mowbray Maternity Hospital Milk 
Depot in Cape Town, while calcium and phosphate were analyzed at both 
Bloemfontein and Cape Town Pathcare laboratories. 
 
 
3.12.1 Measurement of Macro-nutrients: 
 
Methodology of the test  
 
The Miris Human Milk Analyzer (manufactured by Miris) was evaluated for breast 
milk analysis at the University Hospital in Lund, Sweden.  All components were 
analyzed in a single run and the accuracy of the tests was extremely high.  The 
Miris Human Milk Analyzer uses infrared transmission spectroscopy, which is 
based on approved IR-technology in combination with a new, unique patented 
technique.  
 
Quality Assurance  
On board quality assurance 
 
 
3.12.2 Measurement of Micro-nutrients: 
 
For the analysis of the micro-nutrients the DXC 800 analyzer (manufactured by 
Beckman Coulter) was used. 
 
Methodology of the tests: 
 
Phosphate  
A timed-rate method using a PHOSm reagent measured the phosphorus 
concentration in the samples.  The inorganic phosphorus reacted with 
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nammonium molybdate in an acidic solution to form a colored phosphomolybdate 
complex (107 Beckman Coulter October 2006). 
 
Calcium  
The total calcium concentration in the samples was measured by indirect 
potentiometry.  Calcium ion selective electrodes were used in conjunction with a 
sodium reference electrode.  A calcium ion selective electrode measured the 
unbound free calcium ions in the solution (108, Beckman Coulter, October 2005). 
 
Quality assurance  
Synchron 1, 2 and 3. 
 
 
3.13 STATISTICAL ANALYSIS 
 
The data for this study was analyzed by the STATISTICA®’ 98 Edition, Statsoft 
Inc. Software.  Linear and logistic regression analyses were used to determine 
the effect of HIV on the nutrient composition of breast milk.  Descriptive statistics 
were used to present data in both tabled and graphic format.  Categorical data 
was compared using the chi-square non-parametric analysis.  A p-value of less 
than 0.5 was considered to be significant.  
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The results in this chapter will focus on socio demographic status, 
haematological data and milk composition.  The results are given in table and 
figure form with emphasis on the significant differences.  The study population 
consisted of 60 mothers who were divided into two groups of 30 mothers each.  
Group one consisted of HIV non-infected mothers who were also the control 
group.  Group two consisted of HIV-infected mothers who did not receive any 
treatment. 
 
4.1 Socio-economic status 
 
Firstly, the number of people contributing to the household income of the 
respondents will be discussed. 
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Figure 4.1: Number of people contributing to household income (n=60). 
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There was a significant difference between the number of people contributing to 
the household income (p=0.0051).  Seven (23.33%) of the mothers living with 
HIV had no financial support or financial income to support them in the 
upbringing of their children, seventeen (56.67%) had one person contributing to 
the household income and six (20.99%) had two people contributing to their 
household income.  In the HIV non-infected group 20 (66.67%) mothers had one 
person contributing to household income and ten (33.33%) mothers had two 
people contributing to their household income.  The employment status of both 
the respondent groups showed a significant difference (p < 0.0001), see Table 
4.1. 
 
Table 4.1: Employment status of the study population (n=60) 
Parameters HIV non-infected 
(n=30) 
HIV-infected 
(n=30) 
Fisher’s Exact 
Test 
Employment status 
Housewife by choice 
   
 
p < 0.0001* 
24 (80%) 9 (30%) 
Unemployed      2 (6.67%)    16 (53.33%) 
Self employed      1 (3.33%)        0 (0%) 
Salary earner   3 (10%)     4 (13.33%) 
Other 0 (0%)  1 (3.33%) 
p-value* - shows a significant difference with a value < 0.05 
 
In the HIV non-infected group 24 (80%) most mothers were housewives by 
choice, two (6.67%) were unemployed, one (3.33%) was self employed and three 
(10%) were salary earners.  In the group of mothers living with HIV, nine (30%) 
mothers were housewives by choice, 16 (53.33%) unemployed, four (13.33%) 
salary earners and one (3.33%) had other means of income.  In light of this we 
also looked at the availability of water, electricity and if the respondents had 
access to refrigeration.  Figure 4.2 shows the percentages for the basic 
household necessities of the two different respondent groups. 
 57 
  p-value* - shows a significant difference with a value < 0.05 
  Figure 4.2: Basic household necessities of the study population (n=60) 
   
There was no significant difference between the two respondent groups with 
reference to the availability of water sources (p=0.1124), electricity (p=0.4915) or 
refrigeration (p=0.7755).  In the HIV non-infected respondent group, 29 (96.67%) 
mothers had access to running tap water in their homes and one (3.33%) had 
another source of tap water.  In the group of mothers living with HIV, 25 (83.33%) 
mothers had access to running tap water in their homes, four (13.33%) had 
access to running tap water outside their homes and one (3.33%) had another 
source of tap water. 
 
With reference to the availability of electricity in the homes of both groups, 30 
(100%) mothers in the HIV non-infected respondent group had electricity in their 
homes and in the group of mothers living with HIV, 28 (93.33%) had electricity in 
their homes and only two (6.67%) did not.  Twenty five (83.33%) mothers in the 
HIV non-infected group and 24 (80%) mothers living with HIV had fridges in their 
homes.  In the HIV non-infected respondent group four (13.33%) mothers did not 
have fridges in their homes and one (3.33%) mother used a neighbor’s fridge.  In 
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the group of mothers living with HIV, three (10%) mothers did not have fridges in 
their homes and three (10%) used a neighbor’s fridge (Figure 4.2). 
 
Table 4.2 shows the percentage of exclusive breastfeeding between the two 
respondent groups.  There were no significant differences between the 2 
respondent groups with reference to exclusive breastfeeding (p=0.3533).  In the 
HIV non-infected group 26 (86.67%) mothers breastfed exclusively and four 
(13.33%) did not.  The frequency of breastfeeding in this group was as follows: 
24 (92.31%) mothers breastfed eight times a day, one (3.85%) mother 20 times a 
day and one (3.85%) 24 times a day.  In the group of mothers living with HIV, 29 
(96.67%) breastfed exclusively and one (3.33%) did not.  The frequency of 
breastfeeding in this group was as follows: one (3.45%) mother breastfed three 
times a day, one (3.45%) four times a day and 27 (93.10%) seven times a day.  
Without a doubt, the demographic questionnaire indicated that both respondent 
groups thought that their breast milk was the ultimate baby food. 
 
Table 4.2 : Exclusive breastfeeding comparison between the respondent groups 
p-value* - shows a significant difference with a value < 0.05 
 
 
4.2 Haematological and immunological data 
 
Table 4.3 shows the median, mean, standard deviation, minimum value, 
maximum value, normal ranges and p-value of each of the haematological and 
immunological parameters for the two respondent groups. The WBC, MCHC, Plt, 
Parameters HIV non-infected 
(n=30) 
HIV-infected 
(n=30) 
p-value 
Exclusive breastfeeding 
Yes 
   
0.3533 26 (86.67%) 29 (96.67%) 
No   4 (13.33%) 1 (3.33%) 
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neutrophil, eosinophil and basophil median values were within the normal 
reference ranges for both respondent groups.  The significant differences can be 
seen in the following variables between the two respondent groups: RBC (p 
<0.0001), Hb levels (p = 0.0119), Hct (p = 0.0031), MCV            (p = 0.0005), 
MCH (p = 0.0043) and monocyte count (p = 0.0275) (see Table 4.3). 
 
In the respondent group of women living with HIV, the median as well as the 
mean values of the following variables showed a decrease in value: RBC, Hb 
level and the Hct.  With the exception of the Hb, the RBC and Hct counts were all 
within normal range. The following variables showed elevated results: MCV, 
MCHC and the monocyte differential count. Although elevated, these variables 
were still within the normal ranges.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
Table 4.3: Haematological parameters for the study population 
 
Haematological 
Variables 
 
Group 
(n=30) 
 
Median 
 
 
Mean 
 
 
SD 
 
 
Minimum 
 
 
Maximum 
 
 
Normal 
ranges 
 
 
p-value 
 
WBC (10³/μℓ) 
Neg 6.64 6.91 2.13 3.46 12.30  
4.0-11.0 
 
0.7618 Pos 6.59 6.78 2.31 3.48 13.5 
 
RBC (10
6
/μℓ) 
Neg 4.72 4.69 0.38 3.93 5.38  
3.7-5.3 
 
<0.0001* Pos 4.00 3.88 0.54 2.83 4.97 
 
Hb (g/dℓ) 
Neg 12.70 12.56 1.57 7.90 15.10  
12.0-16.0 
 
0.0119* Pos 11.60 11.42 1.82 6.80 14.70 
 
Hct (ℓ/ℓ) 
Neg 0.40 0.39 0.04 0.28 0.45  
0.35-0.45 
 
0.0031* Pos 0.36 0.35 0.05 0.21 0.44 
 
MCV (fℓ) 
Neg 84.00 83.43 6.98 61.00 94.00  
81-100 
 
0.0005* Pos 90.00 91.43 10.88 67.00 123.00 
 
MCH (pg) 
Neg 27.5 26.93 2.88 17.00 31.00  
28.0-35.0 
 
0.0043* Pos 29.00 29.63 3.93 21.00 38.00 
 
MCHC (g/dℓ) 
Neg 32.00 32.27 1.39 28.00 34.00  
32.0-37.0 
 
0.6692 Pos 32.00 32.47 1.66 29.00 37.00 
 
Plt (10³/μℓ) 
Neg 337.50 334.93 73.31 205.00 468.00  
140-420 
 
0.5161 Pos 346.00 350.83 111.32 150.00 656.00 
Neutrophils 
(10³/μℓ) 
Neg 3.62 3.95 1.94 1.16 9.26  
2.0-7.5 
 
0.8245 Pos 3.29 3.89 1.96 1.34 9.46 
Lymphocytes 
(10³/μℓ) 
Neg 2.27 2.33 0.51 1.55 3.89  
1.0-4.0 
 
0.1808 Pos 2.04 2.14 0.80 0.92 4.27 
Monocytes 
(10³/μℓ) 
Neg 0.39 0.42 0.15 0.19 0.81  
0.0-0.8 
 
0.0275* Pos 0.49 0.51 0.18 0.24 0.98 
Eosinophils 
(10³/μℓ) 
Neg 0.12 0.19 0.19 0.01 0.76  
0.0-0.4 
 
0.4197 Pos 0.16 0.21 0.23 0.02 1.07 
Basophils 
(10³/μℓ) 
Neg 0.02 0.03 0.02 0.01 0.1  
0.0-0.1 
 
0.9256 Pos 0.02 0.03 0.01 0.01 0.07 
 
 
 
 
A significant difference in both subject groups with reference to the 
immunological status were detected (p < 0.0001) (see Table 4.4). 
p-value* shows a significant difference with a p-value <0.05 
SD=standard deviation, WBC = white blood cells, RBC = red blood cells, Hb = hemoglobin, Hct = hematocrit, MCV = 
mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin 
concentration, Plt = platelets 
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Table 4.4: Immunological parameters for the study population  
Haematological 
Variables 
Group 
(n=30) 
Median 
 
Mean 
 
SD 
 
Minimum 
 
Maximum 
 
Normal 
ranges 
 
p-value 
 
Total T Cell Count (cm
2
) 
Neg 1709.50 1715.90 437.19 1051.00 2991.00  
1100-1700 
 
0.9832 
 
Pos 1756.00 1770.93 735.25 712.00 3742.00 
 
CD 4 Count (cm
2
) 
Neg 988.00 992.30 290.44 549.00 1958.00  
700-1100 
 
<0.0001* Pos 430.50 577.97 377.72 138.00 1447.00 
 
CD 8 Count (cm
2
) 
Neg 620.50 658.93 211.37 339.00 1050.00  
500-900 
 
<0.0001* 
Pos 1081.50 1138.57 467.13 498.00 2452.00 
 
CD4/CD8 Ratio 
Neg 1.64 1.61 0.51 0.81 2.78  
1.0-1.5 
 
<0.0001* Pos 0.42 0.53 0.31 0.10 1.27 
 
HIV viral load (cps/mℓ) 
Neg - - - - - - - 
Pos 676 37812 95462 40 478135 - - 
 
 
 
 
4.3 Composition of milk nutrients  
 
Table 4.5 shows the median, mean, standard deviation, minimum value, 
maximum value, normal ranges and p-value of each of the chemical variables for 
the two subject groups.  The only significant differences that could be seen in the 
following variables between the two groups were the percentage proteins (p = 
<0.0001) and calcium levels (p = 0.0081).  The median as well as the mean 
values of the proteins were elevated in the subject group of mothers living with 
HIV.  The calcium levels in the same group showed a decrease in both median 
and mean values. The reference ranges used in Table 4.5 were obtained from 
previous studies. 
 
 
 
 
p-value* shows a significant difference with a p=value <0.05 
SD=standard deviation 
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Table 4.5: Composition of milk nutrients 
Variables Group 
(n=30) 
Median 
 
Mean 
 
SD 
 
Minimum 
 
Maximum 
 
Normal 
ranges 
p-value 
Fat 
(%) 
Neg 2.85 4.14 4.10 0.80 18.00 3 – 5 % 
a
 
4.5 % 
b
 
 
0.3146 Pos 3.10 4.32 4.54 1.30 26.90 
Proteins 
(%) 
Neg 0.90 1.05 0.79 0.10 4.00 0.8 – 0.9 % 
a
 
1.1 % 
b
 
 
<0.0001* Pos 1.80 2.04 1.50 0.50 7.50 
Lactose 
(%) 
Neg 5.75 5.79 1.20 1.80 10.50 6.9 – 7.2% 
a
 
6.8 % 
b
 
 
0.1427 Pos 5.45 5.46 1.52 1.90 7.80 
Energy 
(kcal/100mℓ) 
Neg 55.00 66.53 41.91 32.00 211.00  
60 – 75 
a
 
 
0.1450 Pos 61.50 70.20 39.19 33.00 263.00 
Calcium 
(mmol/ℓ) 
Neg 5.43 5.33 0.90 3.75 7.10 2.5 – 3.0 
mmol/ℓ 
a
 
 
0.0081* Pos 4.43 4.49 1.57 0.65 8.15 
Phosphate 
(mmol/ℓ) 
Neg 1.43 1.52 0.47 0.50 2.85 1.3 – 1.6 
mmol/ℓ 
a
 
 
0.1448 Pos 1.18 1.34 0.72 0.50 2.95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p-value * shows a significant difference with a p-value < 0.05 
SD=standard deviation 
a 
Values obtained from the Perintol, 1979. 
b 
Values obtained from Mustafa, 2001 
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5.1 INTRODUCTION 
 
Since the first case of HIV and AIDS was reported 25 years ago, it has become 
one of the most highly studied diseases in history.  The complexity, place-
specific, social, economic, behavioral and psychological drivers of the spread of 
HIV and AIDS remain less well-delineated.  And still unfolding today is the 
consequences of increased illness and death in poor communities and countries 
(Gillespie, Greener, Whiteside & Whitworth, 2007).  
 
5.2 SOCIO-ECONOMIC STATUS 
 
There is an increasing interest among researchers with regard to the relationship 
between SES and health.  The physical and social environment in which 
individuals work and live is associated with SES.  Individuals with fewer socio-
economic resources usually encounter less social support and have decreased 
access to means for restoring and maintaining health (Adler & Snibbe, 2003).  
The inverse relationship between SES and health is one of the most consistent 
social epidemiological findings.  The SES-health relationship is not only found in 
more developed and industrial countries, but also in developing countries such 
as South Africa (Mulatu & Schooler, 2002).  
 
Two variables that differed significantly between the two respondent groups were 
the number of people contributing to the household income (p=0.0051) as well as 
the respondents’ employment status (p<0.0001).  The question that arises is 
whether income and employment levels have independent effects on an 
individual’s health status (See Figure 4.1 and Table 4.1). 
CHAPTER 5 
DISCUSSION 
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South Africa is a country struggling with a legacy of poverty and economic 
inequality in the midst of an HIV epidemic and is one of the countries which is 
affected the worst (Gillespie et al., 2007; Booysen & Summerton, 2002).  In 2005 
a United Nations publication stated that poverty increases vulnerability to HIV 
and AIDS.  This statement is complex in the fact that the HIV burden is 
concentrated mainly in the poorest regions of the world but not always among the 
poorest populations in the areas.  In South Africa, for example, the prevalence 
rates of HIV are highest among the youth living in poor urban informal 
settlements as compared to other areas (Gillespie, Kadiyala & Greener, 2007; 
Dinkelman, Lam & Leibbrandt, 2007; Booysen & Summerton, 2002). 
 
In the 1990’s, The New England Journal of Medicine, published various articles 
which documented marked differences in death rates among individuals at 
different income and educational levels.  These showed that there was a graded 
association between income and mortality and that the effect was greatest at the 
lowest income levels, especially for infant mortality (Adler & Snibbe, 2003). 
Consequently, higher incidence and prevalence of health problems, disease and 
death are associated with a lower SES.  This negative relationship can be found 
whether social inequality is measured at individual level or at the level of 
neighborhood community or even society (Mulatu & Schooler, 2002). So it is 
often argued that poverty is the root cause of the spread of HIV (Gillespie et al., 
2007).  
 
The results that were obtained in reference to household necessities, showed no 
significant difference between the two respondent groups’ water sources 
(p=0.1124), electricity (p=0.4915) and refrigeration (p=0.7755).  Based on this, it 
could be argued that should the mother choose not to breastfeed her child, she 
would have the means available to her for alternative feeding.  If a mother 
whished to bottle feed her child, she would need access to clean water, 
refrigeration and materials for boiling water.  This study showed that these 
 65 
mothers, HIV-infected or not, did indeed have access to water and sanitation 
infrastructure (See Figure 4.2).   
 
Since the outbreak of HIV more than 25 years ago, there have been numerous 
debates about whether an HIV-infected mother should breastfeed or not even 
though the benefits of breast feeding have been proven and established 
throughout the years (Anatolitou, 2012; Symon, 2012). Although the HI-virus can 
be transmitted through breastfeeding and this should be taken into account, there 
are many more factors to consider before making a decision about infant feeding.  
No significant differences were found in this study with reference to exclusive 
breastfeeding (p=0.3533).  Although all the respondents regarded their breast 
milk as the best food for their babies, the choice to breastfeed whether or not 
there is HIV infection, still remains a personal one. 
 
The South African Government stated in August 2011 that South Africa is one of 
only 12 countries in the world where infant mortality has been on the increase.  
The Tswane declaration in support of excusive breastfeeding was therefore 
brought to light and the 2010 WHO guidelines on HIV and infant feeding which 
recommend that all HIV infected mothers should breastfeed, were adopted. As 
such, it has been recommended that South Africa moves to an exclusive 
breastfeeding strategy, except when an authorized health practitioner 
recommends milk formula (Department of Health, 2012). 
 
5.3 HAEMATOLOGICAL AND IMMUNOLOGICAL VARIABLES 
 
5.3.1 Haematological Variables 
 
Haematological variables are sometimes difficult and intriguing to interpret, 
because when the results are put into perspective, there are always other 
variables excluded from the study, which may have been worth analyzing for 
interpretation purposes.  
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In this study there were a few statistical differences in the haematological 
variables of the different respondent groups.  Significant differences were seen in 
the decreased values of the RBC (p<0.0001), Hb (p=0.0119) and Hct (p=0.0031) 
(see Table 4.3).  RBC, also known as erythrocytes, contains Hb which transports 
oxygen (O2) and carbon dioxide (CO2) acts as acid-base buffer and supply 
energy and ions to the body.  The RBC count usually rises or falls with the Hb 
and Hct parameters, but decreases in conditions such as anemias, hemolysis, 
chronic renal failure, hemorrhage and failure of marrow production (Curry, 2012), 
since it shows the number of red blood cells per unit volume of blood.  
 
An important clinical problem in HIV-infected patients and those with AIDS is 
anemia. Since blood loss is the most obvious cause of anemia, the 
pathophysiology of HIV-associated anemia may include three basic meganisms, 
a decrease in red blood cell production, an increase in red blood cell destruction 
or ineffective red blood cell production (Masaisa, Gahutu, Mukiibi, Delanhe & 
Philippé, 2011; Behler, Shade, Gregory, Abrams, Volberding, 2005).  
 
Decreased RBC production - may be a consequence of infiltration of the bone 
marrow by neoplasm, infection, use of myelosuppressive medication, HIV 
infection itself, a decreased production of endogenous erythropoietin, blunted 
response to erythropoietin or hypogonadism (Masaisa, Gahutu, Mukiibi, Delanhe 
& Philippé, 2011; Behler et al., 2005; Claster, 2002). 
 
Increased RBC destruction – premature or increased RBC destruction in the 
spleen or the circulator system may occur in patients with HIV infection.  
Hemolytic anemia may occur as a result of RBC autoantibodies, hemophagocytic 
syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic 
purpura or glucose-6-phosphate dehydrogenase deficiency (Masaisa, Gahutu, 
Mukiibi, Delanhe & Philippé, 2011; Behler et al., 2005; Claster, 2002). 
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Ineffective RBC production – may result from nutritional deficiencies, most 
commonly, deficiencies in iron, folic acid or vitamin B12.  In HIV-infected persons, 
folic acid deficiency is generally caused by either dietary deficiency or jejunal 
pathology (Masaisa, Gahutu, Mukiibi, Delanhe & Philippé, 2011; Behler et al., 
2005; Claster, 2002).  
 
Hemoglobin is the main component of red blood cells and serves as the 
transporter of O2 and CO2 in the blood.  The Hb can be used to determine the 
presence of anemia or polycythemia (Merritt, 2012) and the Hct is the fraction of 
whole blood composed of RBC.  Causes of a decrease in Hct include, but are not 
limited to anemia, bleeding, red blood cell destruction, bone marrow suppression 
or underproduction, malnutrition and nutritional deficiencies, infection, 
overhydration and pregnancy (O’Leary, 2012).  Studies have shown that 
hemoglobin is an independent prognostic factor in both ART-naїve individuals 
and those commencing therapy (British HIV Association guidelines, 2012).  The 
Hb levels of the HIV-infected group were lower than the normal reference levels 
and were also lower than the Hb levels of the control group (see Table 4.3).  The 
risk factors currently associated with anemia in HIV infection could include: a 
history of clinical AIDS, a CD4 cell count less than 200 cells/μℓ, plasma viral load, 
women, black race, Zidovudine use, increasing age, lower body mass index, 
history of bacterial pneumonia, oral candidiasis and a history of fever. 
 
The variables that showed an increase were the MCV (p=0.0005), MCH 
(p=0.0043) and the monocyte count (p=0.0275).  The increases in the above 
mentioned parameters were evident in the values of the HIV-infected respondent 
group, but were still within normal reference ranges (see Table 4.3).  MCV is the 
average volume of red cells in a specimen and is elevated or decreased in 
accordance with the average red cell size.  A high MCV indicates macrocytic 
(large average RBC size), a common cause of macrocytic anemia (increased 
MCV) as well as folate deficiency anemia, Vitamin B deficiency anemia, liver 
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disease, hemolytic anemias, hypothyroidism, excessive alcohol intake, aplastic 
anemia and myelodysplastic syndrome (Curry, 2012).  
 
MCH is the content (weight) of Hb of the average red cell.  MCH is an indicator of 
red blood cell, used in the diagnosis of anemia to determine if an anemia is hypo, 
normo or hyperchromic.  MCH on its own does not add significant, clinically 
relevant information (Merritt, 2012).  The WBC count, on the other hand, is a 
component of a complete blood cell count and is the enumeration of white blood 
cells in a small volume of whole blood.  The only variable that showed a 
significant difference was the monocyte count (p=0.0275) (see Table 4.3).  
Monocytes are phagocytes or myeloids that surround, engulf and digest bacteria 
or other particles.  Common causes of an elevated monocyte count or 
monocytosis include chronic infections such as tuberculosis, bacterial 
endocarditis, rickettsiosis, malaria, collagen vascular disease and inflammatory 
bowel disease (Naushad, 2012). 
 
5.3.2 Immunological Variables 
 
The only two immunological variables tested in this study were the CD4 cell 
count and viral load.  These two immunological variables are the most common 
markers used for HIV confirmation and are also used for the initiation of therapy.  
The respondents’ HIV status was obtained from their medical records and CD4 
cell counts as well as a viral load were done on their blood and used as a 
confirmatory test.  
 
The CD4 cell count is used as a guideline for the initiation of treatment for HIV-
infected persons and is required to accurately assess the immune status of any 
given patient at any given time.  HIV has a particular tropism for cells with the 
CD4 protein on their surface.  Macrophages, glial cells in the brain, T-helper cells 
and T-regulator cells all have CD4 on their surfaces.  CD4+ T cells can be lost 
through a number of mechanisms and cell death can occur as part of the natural 
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immune response and cell activation that occurs with any chronic infection.  HIV 
itself is also directly cytotoxic to T cells.  Long before these mechanisms were 
fully understood, AIDS was characterized by a specific loss of CD4+ T cells 
(Bennett, 2012). 
 
Several areas of the immune system are affected by the loss of CD4+ T cells.  
Both cellular CD8 responses and humoral antibody responses become less 
effective due to the lack of T-cell help.  In adults, the CD4+ T cell count has the 
most influence.  CD4 is a protein that lives on the surface of infection fighting 
WBC called T-helper cells.  HIV targets these immune cells.  The CD4 count 
declines over time in untreated individuals and may vary from time to time (see 
Table 4.4).  In people infected with HIV who are not getting treated, CD4 cell 
counts generally decreases as HIV progresses (Carpenter, 2012).  The positive 
subject group’s mothers are known to be living with HIV, without receiving any 
treatment.   
 
The mean value of the CD4 cell count of the HIV-infected respondents was  
577 cells/mm3; this is lower than the normal reference ranges as given in Table 
4.4. Persons with a CD4 cell count above 350 cells/mm3 are usually 
asymptomatic or early stage infection, although they have enlarged lymph nodes.  
The immunological results obtained in Table 4.4 showed a comparison between 
the early stages of HIV infection and the haematological findings in Table 4.3.  
The length of the asymptomatic phase varies from person to person, lasting 
anything form six to eight years in most people.  In about five to ten percent of 
people it can last for many years and in some for decades.  In others there is a 
rapid fall in the CD4 cell count and progression to the symptomatic phase 
happens within six to 12 months (Carpenter, 2012). 
 
Primary HIV infections are associated with high plasma viral loads (see Table 
4.4).  These viral loads decline about four to six months after infection to a nearly 
steady level, with a small but asymptomatic phase of infection.  In the advanced 
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stages of HIV, the viral load increases sharply, coinciding with the onset of AIDS.  
The viral load has long been established as a strong predictor of the rate of 
disease progression and may influence the choice of antiretroviral agents (British 
HIV Association guidelines, 2012). 
 
5.4 MACRO- AND MICRO NUTRIENTS 
 
No significant differences were seen between the two respondent groups with 
reference to the fat (p=0.3146), lactose (p=0.1427), energy (p=0.1450) and 
phosphate levels (p=0.1448).  The significant differences were in the percentage 
protein (p<0.0001) and calcium levels (p<0.0081) (see Table 4.4).  Human milk 
contains a wide variety of proteins that contribute to its unique qualities, so due to 
financial constraints, this study could only analyze the total protein levels of said 
milk.  The fact that only the proteins were analyzed made interpretation difficult.  
Human milk proteins provide an important source of amino acids to rapidly 
growing infants and also play a role in facilitating the digestion and uptake of 
other nutrients in breast milk.  Breast milk proteins exert numerous physiologic 
activities such as the enhancement of immune function, defense against 
phatogenic bacteria, viruses and yeast, and the development of the gut and its 
functions (Lönnerdal, 2003).  In this study, the protein levels among the HIV-
infected respondent group showed an elevation (see Table 4.4).  Comparison to 
other studies was particularly difficult since a wide variety of analytical methods 
had been used over years in these studies.  Several different methods were used 
for protein analysis in different studies and yielded different results 9g/ℓ (WHO, 
2009) for mature milk and 14-16g/ℓ during early lactation (Lönnerdal, 2003).  It 
was shown that protein concentration changes as lactation progresses.  Although 
the protein content of human milk decreases rapidly during the first month of 
lactation and the decline is much slower after, it is relatively invariable between 
women at any given stage of lactation (WHO, 2002).  In general it appears that 
neither protein malnutrition nor protein supplementation has little if any effect on 
the protein concentration in human milk (Lönnerdal, 2003). 
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Calcium is essential for tissue formation, bone structure and function and its 
metabolism is modulated by other nutrients, hormones and trace elements (Loui, 
Raab, Obladen & Brätter, 2002).  In this study, the calcium levels of the HIV-
infected group were lower than those of the HIV non-infected group and both 
respondent groups’ calcium levels were higher than the reference ranges given 
(see Table 4.4).  Comparison to other studies was particularly difficult since a 
wide variety of analytical methods were used over years in these studies.  As 
said by the WHO, human milk contains 250-300mg/ℓ calcium with no pronounced 
changes during lactation.  Maternal diet does not appear to influence the 
concentration of calcium in milk, but recent studies from Gambia (2002) indicated 
that poorly nourished women on low calcium diets produced milk with lower than 
normal calcium levels, which did not increase with calcium supplementation 
(WHO, 2002). 
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The HIV pandemic has caused an ongoing debate about the best way for HIV-
infected mothers to feed their children.  This has led to confusion around infant 
feeding messages and an erosion of breastfeeding practices since HIV can be 
transmitted from mother-to-child trough breastfeeding.  In developing countries 
the key issue in HIV-affected populations is reduced to decisions on how to 
balance the hazards of MTCT of HIV, against the risks of mortality and 
heightened morbidity among infants. 
 
6.1 CONCLUSION 
 
Since there is very limited research data available in the 20th century concerning 
the effect of HIV on breast milk, the results of this study could prove useful for 
future investigations dealing with the effect of HIV on the nutrient composition of 
breast milk.  This study originated from the question whether HIV had an effect 
on the nutrient composition of breast milk. 
 
Previous studies (Adler & Snibbe, 2003; Malatu & Schooler, 2002) implied that 
SES had a direct influence on the prevalence of HIV and that health problems of 
individuals associated with different levels of SES were not necessarily 
associated with socio-economic class itself, but rather with the associated factors 
related to the different levels of socio-economic status such as HIV. 
 
In conclusion, the results from this study indicate that there are differences in the 
nutrient composition of breast milk of mothers that are HIV-infected.  The 
differences can be seen in the percentage proteins and calcium levels of breast 
milk.  Although limited research data was available, the normal reference ranges 
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on the composition of breast milk showed a correlation between the results 
obtained from this study to those from other studies.  However, it also seems that 
if the individual is relieved from the burden associated with a specific socio-
economic background, everyone seems to have the same health status. 
 
6.2 RECOMMENDATIONS 
 
The results from this study clearly underline the need for further investigation.  
The same study design can be used but a larger study population should be 
included in a subsequent study.  The true effect of SES on the prevalence of HIV 
can also be evaluated.  The problem associated with the interpretation of the 
results is hidden within the fact that the word "socio-economic status" could be 
very controversial, as no quantitative value could be ascribed directly to it.  
 
Only a limited panel of tests could be performed on the composition of the breast 
milk.  Further investigations need to be done on the composition of breast milk 
with a wider range of tests being conducted. 
 
Major factors influencing the public’s point of view on HIV and breastfeeding that 
need urgent attention include the role of peer pressure, advertising, government 
health regulations and general breastfeeding education.  However, it will not be 
easy to evaluate the specific role of these factors on the mothers’ feeding choice 
for her infant.  From this study we can indicate that breast is still regarded as the 
best. 
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